{"AllianceGenome": "427", "HGNC": "427", "MIM": "105590", "_id": "238", "_version": 2, "accession": {"genomic": ["AC074096.8", "AC093756.3", "AC098874.6", "AC106870.4", "AC106899.5", "AF032882.1", "CH471053.2", "CP068276.2", "EU660517.1", "EU660518.1", "EU660519.1", "EU660520.1", "EU660521.1", "EU660522.1", "EU660523.1", "EU660524.1", "EU660525.2", "EU660526.1", "EU660527.1", "GM868985.1", "JB025728.1", "KF437290.1", "KF667483.1", "KU954549.1", "KU954551.1", "NC_000002.12", "NC_060926.1", "NG_009445.1"], "protein": ["AAB71619.1", "AAC51104.1", "AAX76514.1", "AAX88892.1", "AAX93126.1", "AAY15027.1", "ACD03579.1", "ACD03580.2", "ACD03581.1", "ACD03582.1", "ACD03583.1", "ACD03584.1", "ACD03585.1", "ACD03586.1", "ACD03587.2", "ACD03588.1", "ACD03589.1", "ACI47591.1", "ACI47592.1", "ACI47593.1", "ACI47594.1", "ACI47595.1", "ACI47596.1", "ACI47597.1", "ACI47598.1", "ACY79560.1", "ACY79561.1", "ACY79562.1", "ACY79563.1", "ACY79564.1", "ACY79565.1", "ACZ57900.1", "ACZ57901.1", "BAD92714.1", "BAG58942.1", "CAT16962.1", "CCV20015.1", "CRL66424.1", "EAX00506.1", "EAX00507.1", "EAX00508.1", "NP_001340694.1", "NP_004295.2", "Q9UM73.3", "XP_054197220.1"], "rna": ["AB209477.4", "AK296218.1", "DA455128.1", "EU788003.1", "EU788004.1", "EU788005.1", "EU788006.1", "EU788007.1", "EU788008.1", "EU788009.1", "EU788010.1", "FJ838786.1", "FJ838787.1", "GU128152.1", "GU128153.1", "GU128154.1", "GU128155.1", "GU128156.1", "GU128157.1", "LN864494.1", "NM_001353765.2", "NM_004304.5", "U62540.1", "U66559.1", "XM_054341245.1", "XR_001738688.3", "XR_008486309.1"], "translation": [{"protein": "BAD92714.1", "rna": "AB209477.4"}, {"protein": "ACI47596.1", "rna": "EU788008.1"}, {"protein": "CRL66424.1", "rna": "LN864494.1"}, {"protein": "ACI47592.1", "rna": "EU788004.1"}, {"protein": "ACY79563.1", "rna": "GU128155.1"}, {"protein": "ACI47594.1", "rna": "EU788006.1"}, {"protein": "XP_054197220.1", "rna": "XM_054341245.1"}, {"protein": "AAC51104.1", "rna": "U66559.1"}, {"protein": "ACY79565.1", "rna": "GU128157.1"}, {"protein": "ACI47595.1", "rna": "EU788007.1"}, {"protein": "ACY79562.1", "rna": "GU128154.1"}, {"protein": "ACY79561.1", "rna": "GU128153.1"}, {"protein": "NP_004295.2", "rna": "NM_004304.5"}, {"protein": "ACI47593.1", "rna": "EU788005.1"}, {"protein": "ACY79564.1", "rna": "GU128156.1"}, {"protein": "ACZ57901.1", "rna": "FJ838787.1"}, {"protein": "ACZ57900.1", "rna": "FJ838786.1"}, {"protein": "BAG58942.1", "rna": "AK296218.1"}, {"protein": "AAB71619.1", "rna": "U62540.1"}, {"protein": "ACI47591.1", "rna": "EU788003.1"}, {"protein": "NP_001340694.1", "rna": "NM_001353765.2"}, {"protein": "ACI47598.1", "rna": "EU788010.1"}, {"protein": "ACI47597.1", "rna": "EU788009.1"}, {"protein": "ACY79560.1", "rna": "GU128152.1"}]}, "alias": ["ALK1", "CD246", "NBLST3"], "clingen": {"_license": "https://www.clinicalgenome.org/docs/terms-of-use/", "clinical_validity": {"classification": "definitive", "classification_date": "2022-12-30T18:00:00.000Z", "disease_label": "neuroblastoma, susceptibility to, 3", "gcep": "Hereditary Cancer Gene Curation Expert Panel", "moi": "AD", "mondo": "MONDO:0013083", "online_report": "https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_ba9f692d-9b6d-4d46-8bfa-009ec20ae538-2022-12-30T180000.000Z", "sop": "SOP9"}}, "ec": "2.7.10.1", "ensembl": {"gene": "ENSG00000171094", "protein": ["ENSP00000373700", "ENSP00000387488", "ENSP00000414027", "ENSP00000482733", "ENSP00000493203"], "transcript": ["ENST00000389048", "ENST00000431873", "ENST00000453137", "ENST00000498037", "ENST00000618119", "ENST00000638605", "ENST00000642122"], "translation": [{"protein": "ENSP00000493203", "rna": "ENST00000642122"}, {"protein": "ENSP00000373700", "rna": "ENST00000389048"}, {"protein": "ENSP00000414027", "rna": "ENST00000431873"}, {"protein": "ENSP00000387488", "rna": "ENST00000453137"}, {"protein": "ENSP00000482733", "rna": "ENST00000618119"}], "type_of_gene": "protein_coding"}, "entrezgene": "238", "exac": {"_license": "http://bit.ly/2H9c4hg", "all": {"exp_lof": 54.4235659426, "exp_mis": 599.074165379, "exp_syn": 297.407014352, "lof_z": 5.69643801252606, "mis_z": 0.101401353705008, "mu_lof": 3.91034575318e-06, "mu_mis": 5.51693208804e-05, "mu_syn": 2.70438743329e-05, "n_lof": 12.0, "n_mis": 594.0, "n_syn": 319.0, "p_li": 0.522362516846561, "p_null": 4.24410620352913e-10, "p_rec": 0.477637482729029, "syn_z": -0.776223696174574}, "bp": 4863, "cds_end": 30143525, "cds_start": 29416089, "n_exons": 29, "nonpsych": {"exp_lof": 48.6785776484, "exp_mis": 541.639943276, "exp_syn": 268.602059287, "lof_z": 5.44444394858842, "mis_z": 0.165574743948278, "mu_lof": 3.91034575318e-06, "mu_mis": 5.51693208804e-05, "mu_syn": 2.70438743329e-05, "n_lof": 10.0, "n_mis": 534.0, "n_syn": 284.0, "p_li": 0.798147429738318, "p_null": 8.43859537121331e-10, "p_rec": 0.201852569417823, "syn_z": -0.591521155628521}, "nontcga": {"exp_lof": 50.0131476543, "exp_mis": 551.091737092, "exp_syn": 273.557943644, "lof_z": 5.4418947265892, "mis_z": 0.25661766340356, "mu_lof": 3.91034575318e-06, "mu_mis": 5.51693208804e-05, "mu_syn": 2.70438743329e-05, "n_lof": 11.0, "n_mis": 539.0, "n_syn": 299.0, "p_li": 0.532419664177388, "p_null": 1.9338333634551e-09, "p_rec": 0.467580333888779, "syn_z": -0.973981242538674}, "transcript": "ENST00000389048.3"}, "exons": [{"cdsend": 29223496, "cdsstart": 29193223, "chr": "2", "position": [[29192773, 29193922], [29196769, 29196860], [29197541, 29197676], [29207170, 29207272], [29209785, 29209878], [29213983, 29214081], [29220705, 29220835], [29222343, 29222408], [29222516, 29222607], [29223341, 29223900]], "strand": -1, "transcript": "NM_001353765", "txend": 29223900, "txstart": 29192773}, {"cdsend": 29920659, "cdsstart": 29193223, "chr": "2", "position": [[29192773, 29193922], [29196769, 29196860], [29197541, 29197676], [29207170, 29207272], [29209785, 29209878], [29213983, 29214081], [29220705, 29220835], [29222343, 29222408], [29222516, 29222607], [29223341, 29223528], [29225460, 29225565], [29226921, 29227074], [29227573, 29227672], [29228883, 29229066], [29232303, 29232448], [29233564, 29233696], [29239679, 29239830], [29251104, 29251267], [29275098, 29275227], [29275401, 29275496], [29296887, 29297057], [29318303, 29318404], [29320750, 29320882], [29328349, 29328481], [29383731, 29383859], [29531914, 29532116], [29694849, 29695014], [29717577, 29717697], [29919992, 29921586]], "strand": -1, "transcript": "NM_004304", "txend": 29921586, "txstart": 29192773}], "exons_hg19": [{"cdsend": 29446362, "cdsstart": 29416089, "chr": "2", "position": [[29415639, 29416788], [29419635, 29419726], [29420407, 29420542], [29430036, 29430138], [29432651, 29432744], [29436849, 29436947], [29443571, 29443701], [29445209, 29445274], [29445382, 29445473], [29446207, 29446766]], "strand": -1, "transcript": "NM_001353765", "txend": 29446766, "txstart": 29415639}, {"cdsend": 30143525, "cdsstart": 29416089, "chr": "2", "position": [[29415639, 29416788], [29419635, 29419726], [29420407, 29420542], [29430036, 29430138], [29432651, 29432744], [29436849, 29436947], [29443571, 29443701], [29445209, 29445274], [29445382, 29445473], [29446207, 29446394], [29448326, 29448431], [29449787, 29449940], [29450439, 29450538], [29451749, 29451932], [29455169, 29455314], [29456430, 29456562], [29462545, 29462696], [29473970, 29474133], [29497964, 29498093], [29498267, 29498362], [29519753, 29519923], [29541169, 29541270], [29543616, 29543748], [29551215, 29551347], [29606597, 29606725], [29754780, 29754982], [29917715, 29917880], [29940443, 29940563], [30142858, 30144452]], "strand": -1, "transcript": "NM_004304", "txend": 30144452, "txstart": 29415639}], "generif": [{"pubmed": 11809760, "text": "Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth"}, {"pubmed": 11877285, "text": "ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes."}, {"pubmed": 12036886, "text": "ALK-positive anaplastic large cell lymphoma had significantly higher levels of caspase 3, while high expression of the antiapoptotic proteins Bcl-2 and PI9 was almost completely restricted to ALK-negative cases."}, {"pubmed": 12112524, "text": "Novel fusion partners CARS and KIAA1618 (ALO17) have been detected with variant rearrangements of ALK in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor cases."}, {"pubmed": 12115586, "text": "results do not support any involvement of ALK in the stimulation of tumorigenic cell growth or differentiation"}, {"pubmed": 12122009, "text": "midkine binds to ALK and has a role in signal transduction for cell growth and survival"}, {"pubmed": 12185581, "text": "ALK-ShcC signal activation, possibly caused by co-amplification with the N-myc gene, might give additional effects on malignant tumor progression of neuroblastoma.ShcC is a potent substrate of the activated ALK kinase."}, {"pubmed": 12213716, "text": "co-expression of c-Myc and ALK was seen in tumor cells of ALK-positive anaplastic large cell lymphomas; C-Myc may be a downstream target of ALK signaling"}, {"pubmed": 12763927, "text": "novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners in a rare variant of diffuse large B-cell lymphoma"}, {"pubmed": 12800156, "text": "In a case of anaplastic large cell lymphoma, ALK is fused to a portion of non-muscle myosin heavy chain gene, MYH9, localized 6 bp downstream of MSN-ALK in the same exonic sequence, resulting in an in-frame fusion of the two partner proteins."}, {"pubmed": 14563642, "text": "Src-kinases, particularly pp60(c-src), associate with and are activated by NPM-ALK expression in various cells, and in cell lines established from patients with large cell lymphoma"}, {"pubmed": 14656879, "text": "results show a pivotal role for Bcl-XL in ALK-mediated oncogenicity"}, {"pubmed": 14962911, "text": "FOXO3a is a barrier to hematopoietic transformation that is overcome by phosphorylation and cytoplasmic relocalization induced by the expression of NPM-ALK"}, {"pubmed": 15004538, "text": "High dose therapy and stem cell transplantation does not produce long-term disease free survival in patients with recurrent chemotherapy-sensitive ALK-negative large cell lymphoma."}, {"pubmed": 15161657, "text": "STAT3 directly contributes to the high level of TIMP1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma."}, {"pubmed": 15226403, "text": "ALK receptor tyrosine kinase has roles promoting cell growth and neurite outgrowth"}, {"pubmed": 15583856, "text": "ALK has roles in oncogenesis of haematopoietic and non-haematopoietic tumors [review]"}, {"pubmed": 15713979, "text": "Although 9 of 36 patients with cutaneous CD30(+) lymphoproliferative diseases had progression of their disease, neither mutations of the p53 gene nor ALK immunoreactivity were found in any of these biopsies."}, {"pubmed": 15886198, "text": "analysis of differentiation of PC12 cells and human embryonic kidney 293 cells transfected with ALK shows absence of agonist activity of pleiotrophin"}, {"pubmed": 15928040, "text": "ALK-mediated alphaDGK activation is dependent on p60src tyrosine kinase, with which alphaDGK forms a complex; alphaDGK activation is involved in the control of ALK-mediated mitogenic properties."}, {"pubmed": 15933425, "text": "CONCLUSIONS: ALK-ALCL arising in the skin represents a single disease with a broad spectrum of morphology; clinicians and pathologists should be aware of this neutrophil-rich (NR) variant with aggressive clinical presentation."}, {"pubmed": 16153455, "text": "We conclude that Jak3 activation is predominantly restricted to ALK-positive ALCL tumors."}, {"pubmed": 16161041, "text": "Genomic PCR and subsequent sequencing showed that the breakpoints were located in intron 23 of SEC31-like 1 protein-transport protein and intron 20 of ALK"}, {"pubmed": 16254137, "text": "Potent and selective ALK inhibitors may have therapeutic application for anaplastic lymphoma kinase."}, {"pubmed": 16604305, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16623783, "text": "Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract may show ALK immunopositivity but do not show consistent ALK rearrangement by fluorescent in situ hybridization."}, {"pubmed": 16651537, "text": "can be adapted for the identification of known and unknown translocation partners of chimeric ALK fusion proteins involved in oncogenesis"}, {"pubmed": 16709933, "text": "constitutive expression of C/EBPbeta in ALK-positive anaplastic large cell lymphoma and its relationship to NPM-ALK"}, {"pubmed": 16766651, "text": "NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells secrete IL-10 and TGF-beta and express FoxP3, indicating their T regulatory (Treg) cell phenotype."}, {"pubmed": 16825495, "text": "Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma."}, {"pubmed": 16835382, "text": "AUF1 was phosphorylated by ALK in vitro and was hyperphosphorylated in NPM-ALK-expressing cells."}, {"pubmed": 16878150, "text": "recruitment of insulin receptor substrate-1 to activated ALK and the activation of NF-kappaB are essential for the autocrine growth and survival signaling of midkine"}, {"pubmed": 16880530, "text": "ALK has a proapoptotic activity in the absence of ligand, whereas it is antiapoptotic in the presence of its ligand and when the kinase is intrinsically activated."}, {"pubmed": 17071493, "text": "CD26 and cell surface adenosine deaminase are selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma"}, {"pubmed": 17077326, "text": "molecular signature of ALK- anaplastic large-cell lymphoma included overexpression of CCR7, CNTFR, IL22, and IL21 genes"}, {"pubmed": 17274988, "text": "A functional role for Shc and likely FRS2 in ALK-dependant MAP-kinase activation and neuronal differentiation of PC12 cells."}, {"pubmed": 17490616, "text": "This study thus supports the possibility that activated ALK may be important in human breast cancers and potentially activated either through the PTN/RPTPbeta/zeta signaling pathway."}, {"pubmed": 17537995, "text": "identify splicing factor as a novel nucleophosmin 1/anaplastic lymphoma kinase-binding protein and substrate"}, {"pubmed": 17681947, "text": "phosphorylation of ALK in PTN-stimulated cells is mediated through the PTN/RPTPbeta/zeta signaling pathway"}, {"pubmed": 17690253, "text": "JunB is a critical target of mTOR and is translationally regulated in NPM-ALK-positive lymphomas."}, {"pubmed": 17904822, "text": "Pleiotrophin failed to activate anaplastic lymphoma kinase (ALK) in neuroblastoma/glioblastoma cells expressing this receptor. ALK is still an orphan receptor in vertebrates."}, {"pubmed": 17922009, "text": "Oncogenic NPM1-ALK contains the ALK catalytic domain plus NPM1 oligomerization motif and mediates malignant cell transformation by epigenetic silencing of signal transducer and activator of transcription STAT5A in T-cell anaplastic large cell lymphomas."}, {"pubmed": 17998938, "text": "Fusion protein nucleophosmin (NPM)-ALK activates GTPase Rac1 via phosphatidylkinase 3-kinase (PI3K) and protein-tyrosine kinase c-src (Src) in anaplastic large cell lymphoma patients."}, {"pubmed": 18070884, "text": "findings indicate that phosphorylation of the first tyrosine of the YXXXYY motif is necessary for the autoactivation of the ALK kinase domain and the transforming activity of nucleoplasmin/ALK"}, {"pubmed": 18097461, "text": "Translocations or deregulated expression of ALK contribute to oncogenesis and genetic or pharmacological tools, aimed at neutralizing its activity in anaplastic lymphoma [REVIEW]"}, {"pubmed": 18165268, "text": "besides MYCN and ALK, other genes proximal and distal to MYCN are highly expressed in neuroblastoma"}, {"pubmed": 18166835, "text": "ALK is part of a fusion protein linked to histological characteristics in a subset of lung neoplasms."}, {"pubmed": 18220322, "text": "different types of cytogenetic aberrations may involve the ALK gene in ALK-positive diffuse large B-cell lymphoma leading to peculiar immunohistochemical staining patterns [case reports]"}, {"pubmed": 18242762, "text": "EML4-ALK fusion gene product is involved in the carcinogenesis in non-small cell lung carcinomas"}, {"pubmed": 18320074, "text": "EML4-ALK fusions occur in less than 3% of non-small cell lung cancers samples; EML4 and/or ALK amplifications also occur."}, {"pubmed": 18414414, "text": "EML4-ALK fusion transcript is not present in gastrointestinal or breast cancers and is specific to NSCLC."}, {"pubmed": 18451166, "text": "A subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clinically responsive to pharmacologic ALK inhibition."}, {"pubmed": 18458503, "text": "Fluorescence in situ hybridization and molecular studies on the bone marrow aspirate specimens led to the detection of a clathrin (CLTC)/ALK rearrangement."}, {"pubmed": 18549625, "text": "There is a high incidence of ALK expression in anaplastic large cell lymphoma."}, {"pubmed": 18593892, "text": "A lung cancer cell line expressing endogenous variant 3 of EML4-ALK underwent cell death on exposure to a specific inhibitor of ALK catalytic activity."}, {"pubmed": 18594010, "text": "EML4-ALK fusion gene is expressed in lung cancer"}, {"pubmed": 18615104, "text": "high prevalence of anti-ALK antibodies in pediatric ALK-positive ALCL and relationship between minimal residual disease and anti-ALK antibody response"}, {"pubmed": 18660380, "text": "the spectrum of diseases exhibiting ALK translocation should be expanded to include ALK(+) histiocytosis"}, {"pubmed": 18677384, "text": "Complex abnormalities of ALK gene exist in systemic anaplastic large cell lymphoma cases, and different types of ALK gene might lead to different clinical outcome."}, {"pubmed": 18724359, "text": "results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal paediatric malignancy"}, {"pubmed": 18788887, "text": "there is ALK overexpression in rhabdomyosarcomas, most likely independent of fusion status"}, {"pubmed": 18845790, "text": "ATIC associated with nucleophosmin-ALK, and its phosphorylation required ALK activity. ALK-mediated ATIC phosphorylation enhanced its enzymatic activity."}, {"pubmed": 18923523, "text": "data identify ALK as a critical player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments"}, {"pubmed": 18923524, "text": "the anaplastic lymphoma kinase, originally identified as a fusion kinase in a subtype of non-Hodgkin's lymphoma (NPM-ALK) and more recently in adenocarcinoma of lung (EML4-ALK), is also a frequent target of genetic alteration in advanced neuroblastoma"}, {"pubmed": 18923525, "text": "detection of previously unknown mutations in the ALK gene, which encodes a receptor tyrosine kinase, in 8% of primary neuroblastomas"}, {"pubmed": 18974134, "text": "concomitant inhibition of Cdc42 and NPM-ALK kinase acted synergistically to induce apoptosis of ALCL cells"}, {"pubmed": 18990089, "text": "ALK protein contributes to NB(neuroblastoma) oncogenesis providing a highly interesting putative therapeutic target in a subset of unfavourable NB tumours."}, {"pubmed": 19074885, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19131589, "text": "these data highlight the functional diversity of NPM-ALK and provide new research directions for the study of the biology of this oncoprotein."}, {"pubmed": 19135051, "text": "This study demonstrates expression of both ALK protein and ALK mRNA are positively correlated with expression of ALK-associated fusion transcripts."}, {"pubmed": 19147828, "text": "The EML4-ALK transcript cannot be regarded as a specific diagnostic tool for non-small cell lung cancer."}, {"pubmed": 19176054, "text": "Phosphorylation of AKT and mTOR is correlated with anaplastic lymphoma kinase expression in anaplastic large cell lymphoma."}, {"pubmed": 19250532, "text": "ALK-DLBCL is a distinct variant of DLBCL with plasmacytic differentiation, which is characterized by a bimodal age incidence curve, primarily nodal involvement, plasmablastic morphology, aggressive behavior and poor response to standard therapies."}, {"pubmed": 19286999, "text": "ALK signaling leads to the functional inactivation and/or degradation of p53 in JNK and MDM2 dependent manners."}, {"pubmed": 19305144, "text": "The expression of the dual specificity phosphatase CDC25A, is deregulated in Ba/F3 cells expressing the oncogenic protein NPM/ALK and in human cell lines derived from NPM/ALK-positive anaplastic large cell lymphomas."}, {"pubmed": 19386350, "text": "Anaplastic lymphoma kinase immunoreactivity in non-small cell lung carcinomas was associated with transcriptional up-regulation, ALK locus rearrangement, and the presence of EML4-ALK fusion transcript."}, {"pubmed": 19423729, "text": "identified novel reciprocal functional interactions between IGF-IR and NPM-ALK"}, {"pubmed": 19459784, "text": "Reports have have highlighted ALK as a significant player and target for drug development in cancer."}, {"pubmed": 19506219, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19531656, "text": "The NPM/ALK alteration affects diverse cellular pathways, and provide novel insights into NPM/ALK-positive anaplastic large cell lymphoma pathobiology."}, {"pubmed": 19535344, "text": "NPM-ALK kinase has a role in the regulation of responsiveness of tumor cells with cdk dysregulation"}, {"pubmed": 19589272, "text": "This retrospective study evaluated 15 cases of inflammatory myofibroblastic tumours (IMTs) to determine histological atypicality, clinicopathological features, outcomes, and expression of anaplastic lymphoma kinase-1 (ALK1) and p53."}, {"pubmed": 19636007, "text": "Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis."}, {"pubmed": 19656549, "text": "ALK expression was not found in any of our cases of intracranial inflammatory pseudotumors"}, {"pubmed": 19656550, "text": "copy number aberrations of the ALK gene is a frequent genetic event in the development of neuroblastomas"}, {"pubmed": 19667264, "text": "Data show that compared with the EGFR mutant and WT/WT cohorts, patients with EML4-ALK mutant tumors were significantly younger and were more likely to be men."}, {"pubmed": 19667264, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19671850, "text": "Lung adenocarcinomas with ALK rearrangements are uncommon in the western population and represent a distinct entity of carcinomas with unique characteristics."}, {"pubmed": 19717436, "text": "T-cell lymphomas characterized by the expression of anaplastic lymphoma kinase (ALK+ TCL) fail to express the TNFalpha and frequently display DNA methylation of the TNFalpha gene promoter."}, {"pubmed": 19723661, "text": "ALK protein expression was significantly up-regulated in advanced/metastatic compared with localized neuroblastomas; overexpression of either mutated or wild-type ALK defines poor prognosis neuroblastoma patients"}, {"pubmed": 19737969, "text": "The presence of an EML-ALK rearrangement was verified by identifying genomic fusion points in tumor samples representative of breast, colon, and NSCLC."}, {"pubmed": 19834503, "text": "Observational study and meta-analysis of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19887368, "text": "The kinase activation loop in NPM-ALK regulates its tyrosine phosphorylation pattern."}, {"pubmed": 20009909, "text": "ALK gene rearrangements are associated with non-small cell lung cancer."}, {"pubmed": 20101209, "text": "Studies indicate that understanding of familial and syndromic neuroblastoma recently has made considerable progress with the identification of PHOX2B and ALK as NB susceptibility genes."}, {"pubmed": 20169312, "text": "Describe a case of ALK-positive primary systemic anaplastic large cell lymphoma with a long clinical course and extensive cutaneous manifestations."}, {"pubmed": 20185586, "text": "ALK autoantibody titers in anaplastic lymphoma kinase positive anaplastic large cell lymphoma inversely correlated with stage and amount of circulating tumor cells."}, {"pubmed": 20379614, "text": "Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 20393185, "text": "Data show that the TNF/Fas/TRAIL pathway is modulated by nucleophosmin-anaplastic lymphoma kinase in anaplastic large cell lymphoma."}, {"pubmed": 20424160, "text": "Results support the notion that the tumor suppressor effects of SHP1 on NPM-ALK are dependent on its ability to bind to this oncogenic protein."}, {"pubmed": 20428197, "text": "RanBP2/ALK rearrangement are associated with atypical myeloproliferative leukemia."}, {"pubmed": 20451371, "text": "The anaplastic lymphoma kinase gene has similarity to the insulin receptor subfamily of kinases and is emerging as having increased pathologic and potential therapeutic importance in malignant disease."}, {"pubmed": 20554525, "text": "active NPM-ALK, but not a kinase-dead mutant, bound and induced Grb2 phosphorylation in tyrosine 160"}, {"pubmed": 20621063, "text": "zinc alone rapidly activates ALK."}, {"pubmed": 20624322, "text": "EML4-ALK fusion appears to be tightly associated with ALK mRNA expression levels. RACE-coupled PCR sequencing is a highly sensitive method that could be used clinically for the identification of EML4-ALK-positive patients"}, {"pubmed": 20624322, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20632993, "text": "Data show that the ALK crystal structure helps explain the reported unique peptide substrate specificity and the importance of phosphorylation of the first A-loop Tyr1278 for kinase activity."}, {"pubmed": 20695522, "text": "ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded beta-sheet."}, {"pubmed": 20719933, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20719933, "text": "Studies indicate that ALK mutations occur in equal frequencies across all genomic subtypes, but F1174L mutants are observed in a higher frequency of MYCN-amplified tumors and show increased transforming capacity as compared with the R1275Q mutants."}, {"pubmed": 20731666, "text": "Studies indicate that ALK is mutated in 6-9% of sporadic cases, and is either amplified or constitutively activated through mutations."}, {"pubmed": 20805506, "text": "Five members of the miR-17-92 cluster were expressed more highly in anaplastic lymphoma kinase (ALK)(+) anaplastic large-cell lymphoma (ALCL), whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL."}, {"pubmed": 20934803, "text": "Studies indicate that ALK has been found to be rearranged, mutated, or amplified in a series of tumours."}, {"pubmed": 20957039, "text": "demonstrated that PHOX2B drives ALK gene transcription by directly binding its promoter, which therefore represents a novel PHOX2B target"}, {"pubmed": 20970119, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 21030459, "text": "Reports the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy."}, {"pubmed": 21036415, "text": "frequent rearrangement in lung signet-ring cell carcinoma"}, {"pubmed": 21045017, "text": "Serine phosphorylation of NPM-ALK, contributes to its oncogenic potential."}, {"pubmed": 21070126, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 21076462, "text": "The data identify the kidney as a new organ site for ALK-associated carcinomas and VCL as a novel ALK fusion partner."}, {"pubmed": 21107285, "text": "Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer."}, {"pubmed": 21129606, "text": "EML4-ALK fusion gene mutations are widely recognized alterations involved in biology and the clinical management of lung adenocarcinoma.This review reports the molecular bases that have led clinical application of detection for such genetic impairments."}, {"pubmed": 21164297, "text": "Describe an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK staining."}, {"pubmed": 21205076, "text": "brief overview of the role of ALK mutations in neuroblastoma pathogenesis and their implication in future therapeutics [review]"}, {"pubmed": 21233286, "text": "Data show that anaplastic lymphoma kinase (ALK)-comtaining granules are novel mRNA-containing cytoplasmic foci that could protect translatable mRNAs from degradation, contributing to ALK-mediated oncogenicity."}, {"pubmed": 21233844, "text": "selective targeting of the Mdk/ALK axis could help to improve the efficacy of antitumoral therapies for gliomas."}, {"pubmed": 21258247, "text": "ALK gene rearrangement is associated with non-small cell lung carcinoma."}, {"pubmed": 21278610, "text": "ALK gene rearrangement is associated with non-small cell lung carcinoma."}, {"pubmed": 21288922, "text": "Studies indicate ALK as a therapeutic target in patients with ALK-rearranged NSCLC."}, {"pubmed": 21336183, "text": "ALK gene rearrangement is associated with response to pemetrexed therapy in patients with non-small cell lung cancer."}, {"pubmed": 21356191, "text": "EML4-ALK fusion variants have a role in non-small cell lung cancer"}, {"pubmed": 21358343, "text": "High ALK is associated with poor tumor responses to EGFR tyrosine kinase inhibitors in pulmonary adenocarcinoma."}, {"pubmed": 21420271, "text": "New molecular targets are on investigation, such as EML4-ALK translocation."}, {"pubmed": 21430068, "text": "Novel ALK fusions are being identified in various tumors in addition to inflammatory myofibroblastic tumor."}, {"pubmed": 21471522, "text": "MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression."}, {"pubmed": 21474455, "text": "Studies indicate that the best characterized alterations of ALK associated with cancer are gene rearrangements."}, {"pubmed": 21488949, "text": "Case Report: document gastroduodenal involvement of ALK-positive anaplastic large cell lymphoma."}, {"pubmed": 21518927, "text": "p16INK4a/pRb may function as an alternative pathway of oncogene-induced senescence; the reactivation of p16INK4a expression might be a novel strategy to restore the senescence program in some tumors."}, {"pubmed": 21575866, "text": "Identify CH5424802, as a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK."}, {"pubmed": 21587085, "text": "ALK gene rearrangement is associated with non-small cell lung cancer."}, {"pubmed": 21596819, "text": "Results reveal two novel gain-of-function mutations of ALK in certain anaplastic thyroid cancers."}, {"pubmed": 21625996, "text": "Neuroblastoma cell lines often express ALK at high levels."}, {"pubmed": 21632861, "text": "high levels of mutated and wild-type ALK mediate similar molecular functions that may contribute to a malignant phenotype in primary neuroblastoma."}, {"pubmed": 21642865, "text": "Anaplastic lymphoma kinase translocation is associated with pemetrexed efficacy in non-small cell lung cancer."}, {"pubmed": 21656749, "text": "The discovery of the novel KIF5B-ALK variant further consolidated the role of aberrant anaplastic lymphoma kinase signaling in lung carcinogenesis."}, {"pubmed": 21720997, "text": "ALK gene rearrangement is associated with nonsmall cell lung cancer."}, {"pubmed": 21734404, "text": "Finding suggests that variants in the non-mutated ALK gene or another gene linked to it may affect penetrance of the ALK mutations and risk of developing NB in familial cases."}, {"pubmed": 21753699, "text": "Report comprehensive histologic analysis of ALK-rearranged lung carcinomas."}, {"pubmed": 21757253, "text": "The powerful effect of ALK inhibitor on EML4-ALK NSCLC was observed."}, {"pubmed": 21765024, "text": "NPM-ALK induces expression of the growth-promoting receptor ICOS."}, {"pubmed": 21784300, "text": "We found no genome-wide statistically significant associations but identified several plausible candidate genes among findings at p < 5E-05:ALK, TMEM132D, LRRC7, SEMA3A, and STIP1."}, {"pubmed": 21799923, "text": "Alk plays an evolutionary conserved role in ethanol-related behaviors"}, {"pubmed": 21847065, "text": "ALK translocation is associated with non-small cell lung cancer."}, {"pubmed": 21847362, "text": "novel ALK point mutations possessed tumorigenic effects mainly through hyperphosphorylation of Y1604 and activation of downstream oncogenic signaling."}, {"pubmed": 21855164, "text": "ALK rearrangement is strongly associated with ALK immunoreactivity, and was seen only in lung tumours with pure signet-ring morphology and solid growth pattern."}, {"pubmed": 21933749, "text": "In patients with advanced, ALK-positive non-small cell lung cancer, crizotinib therapy is associated with improved survival."}, {"pubmed": 21940108, "text": "We detected the ALK mutation (F1174C and R1275Q) in 2 (3.7%) of the 54 neuroblastoma specimens examined"}, {"pubmed": 21972109, "text": "study reports a novel syndromic presentation associating congenital Neuroblastoma with severe encephalopathy nnd abnormal shape of the brainstem on brain MRI in two unrelated sporadic cases harboring de novo, germline, heterozygous ALK gene mutations"}, {"pubmed": 21989914, "text": "Results demonstrate that the extent and timing of sympathetic neurogenesis is controlled by Midkine and Alk signaling."}, {"pubmed": 22071784, "text": "ALK gene rearrangement is associated with lung adenocarcinomas."}, {"pubmed": 22071890, "text": "ALK deleterious mutations are rare events in neuroblastoma patients with a high probability of predisposition. Other predisposing genes remain to be discovered."}, {"pubmed": 22080568, "text": "findings are important because they provide a molecular basis of ALK-positive lung adenocarcinomas and triple-negative lung adenocarcinomas and further stratify more or less aggressive subgroups of triple-negative lung ADC"}, {"pubmed": 22085494, "text": "The frequency of ALK mutations in neuroblastoma is low and solitary copy number change of it is rarely observed."}, {"pubmed": 22086496, "text": "It was concluded that not all anaplastic lymphoma kinase mutants have neoplastic transformation potential and may represent ''passenger'' mutations in the evolution of cancer."}, {"pubmed": 22124476, "text": "Echinoderm microtubule-associated protein like 4-ALK fusion gene is associated with longer overall survival of lung adenocarcinoma patients with wild-type epidermal growth factor receptor mutations."}, {"pubmed": 22129856, "text": "ALK rearrangement was not a significant prognostic factor in surgically resectable NSCLC."}, {"pubmed": 22134072, "text": "Our findings suggest that ALK positivity is associated with a significantly poor outcome in nonsmoking-related adenocarcinoma and that ALK-positive tumors may be associated with an increased risk of brain and liver metastases."}, {"pubmed": 22135231, "text": "Data indicate that PIK3CA mutations occur in lung adenocarcinomas, usually concurrently with EGFR, KRAS, and anaplastic lymphoma kinase (ALK)."}, {"pubmed": 22157554, "text": "An overview of the diagnostic assays available for detecting ALK rearrangement."}, {"pubmed": 22184391, "text": "ALK aberrations on genomic and protein levels are frequently found in RMSs. ALK may play a role in tumor biology."}, {"pubmed": 22203728, "text": "Data show that CEP-28122 is a highly potent and selective orally active anaplastic lymphoma kinase (ALK) inhibitor, and selective against ALK-positive human cancer cell growth."}, {"pubmed": 22249260, "text": "Our findings provide a novel insight into the mechanism of deregulation of the ALK kinase and its roles in neuroblastoma pathogenesis."}, {"pubmed": 22280150, "text": "rearrangement for ALK locus by fluorescence in situ hybridization was found in one lung and in two central nervous system samples of inflammatory myofibroblastic tumor"}, {"pubmed": 22282022, "text": "in patients with nonsmall cell lung cancer, ALK gene rearrangement was significantly associated with pericardial disease and pleural disease; patients with ALK gene rearrangements and patients with EGFR mutations were predisposed to liver metastasis compared to triple negative cohort"}, {"pubmed": 22286764, "text": "Both wild-type and gain-of-function mutants in ALK are able to stimulate transcription at the MYCN promoter."}, {"pubmed": 22317764, "text": "Data indicate that 266 (76.2%) tumors harbored EGFR mutations, 16 (4.6%) HER2 mutations, 15 (4.3%) EML4-ALK fusions, 7 (2.0%) KRAS mutations, and 2 (0.6%) BRAF mutations."}, {"pubmed": 22327622, "text": "identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma."}, {"pubmed": 22327623, "text": "transforming ability of all of the ALK led to multiple transformed foci formation in culture and in subcutaneous tumors in a nude mouse tumorigenicity assay"}, {"pubmed": 22334013, "text": "ALK mutation is not associated with crizotinib resistance in Non-Small Cell Lung Cancer."}, {"pubmed": 22334442, "text": "The fusion transcript of ALK and PTPN3 identified resulted from translocation of a part of ALK gene into the third intron of PTPN3. Analysis of the transcript sequence indicates that no protein with any enzymatic activity is produced."}, {"pubmed": 22385925, "text": "NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor."}, {"pubmed": 22439933, "text": "Coexpression of activated ALK with MYCN provides prosurvival signals that block this apoptotic response and allow continued expansion and oncogenic transformation of hyperplastic neuroblasts, thus promoting progression to neuroblastoma."}, {"pubmed": 22471704, "text": "review will discuss our current understanding of ALK in human cancer and the implication of recent results for treatment"}, {"pubmed": 22484425, "text": "Expression of MYCN or ALK(F1174L), one of the oncogenic ALK variants identified in primary neuroblastomas, enabled these cells to grow independently of c-MycER(T) activity in vitro and caused formation of neuroblastoma-like tumors."}, {"pubmed": 22569898, "text": "nonsmall cell lung cancers (NSCLC) harboring activating EGFR mutations were more likely to express low ERCC1 and thymidylate synthetase (TS) mRNA levels; patients with NSCLC who had ALK rearrangement were more likely to express low TS mRNA levels"}, {"pubmed": 22570254, "text": "immunohistochemical analysis of ovarian tumor tissue microarray detected aberrant ALK expression in 2% to 4% serous carcinoma patients"}, {"pubmed": 22646268, "text": "This is the first report, to our knowledge, of ALK gene rearrangements in inflammatory myofibroblastic tumors in the female genital tract."}, {"pubmed": 22705117, "text": "ALK gene amplification is a nonrandom and clonally related event in a subset of pulmonary sarcomatoid carcinoma."}, {"pubmed": 22726922, "text": "Extra copies of ALK gene locus are a frequent genetic aberration in both ALK-positive and ALK-negative anaplastic large cell lymphomas and is a favorable prognostic marker for the patients."}, {"pubmed": 22736493, "text": "Lung neoplasm patients who harbor EML4-ALK fusion genes generally have wild type EGFR and KRAS genes."}, {"pubmed": 22743652, "text": "Report histologic subtypes and distinctive cytomorphologic features of ALK-rearranged lung adenocarcinomas."}, {"pubmed": 22743654, "text": "In renal cell carcinoma ALK rearrangement and/or an increase in ALK copy number area associated with poorer prognosis."}, {"pubmed": 22748945, "text": "Testing patients with advanced or metastatic NSCLC for EGFR mutation status may help doctors to determine those who are most likely to respond to EGFR TK inhibitors, tailoring therapy at diagnosis"}, {"pubmed": 22773605, "text": "In six pediatric cases of anaplastic large cell lymphoma the expression of anaplastic lymphoma kinase was confirmed."}, {"pubmed": 22781601, "text": "CD99 is highly expressed in anaplastic large-cell lymphoma, and showed high rate of co-expression with ALK."}, {"pubmed": 22810114, "text": "ALK mutation may be responsible for medulloblastoma."}, {"pubmed": 22892933, "text": "the present study is the first in Latin America to present clinicopathologic information regarding ALK-rearranged NSCLC in patients from this geographic area."}, {"pubmed": 22895149, "text": "ALK rearrangement is associated with response to therapy in metastatic non-small-cell lung cancer."}, {"pubmed": 22932897, "text": "Crystal structures of the ALK kinase domain containing the F1174L and R1275Q neuroblastoma mutation."}, {"pubmed": 23020707, "text": "Discordance between anaplastic lymphoma kinase status occurred in primary non-small-cell lung cancers and their corresponding metastases."}, {"pubmed": 23050789, "text": "We found rearranged ALK in 10 of 19 radiation-exposed papillary thyroid cancer (PTC) cases, but none among 6 patients with PTC with no radiation exposure."}, {"pubmed": 23064464, "text": "inhibition of PDGFRA and PDGFRB in a patient with refractory late-stage NPM-ALK+ Anaplastic large cell lymphoma resulted in rapid, complete and sustained remission"}, {"pubmed": 23070248, "text": "Anaplastic lymphoma kinase gene rearrangement is associated with Hepatoid carcinoma of the lung."}, {"pubmed": 23084186, "text": "The results of the present study support the hypothesis that activated ALK tumors represent a specific subset of neuroblastomas"}, {"pubmed": 23092569, "text": "A known mutation C3375A in ALK was successfully identified in children, and its incidence is not influenced by the clinical features of childhood neuroblastoma."}, {"pubmed": 23104988, "text": "The identification and characterisation of two novel neuroblastoma ALK mutations, is reported."}, {"pubmed": 23139213, "text": "These results indicate that genomic rearrangements constitute an alternative mechanism to ALK point mutations resulting in receptor activation."}, {"pubmed": 23154552, "text": "ALK gene rearrangement is associated with metastasis in non-small-cell lung cancer."}, {"pubmed": 23205942, "text": "The expression of ALK in mycosis fungoides, stage IA."}, {"pubmed": 23289484, "text": "Global genomic comparison with SNP arrays showed tumours with ALK fusion to have fewer alterations in oncogenes and suppressor genes despite a similar overall aberration frequency, suggesting strong oncogenic potency of ALK activation by gene fusion"}, {"pubmed": 23291583, "text": "Case Report: fatal case of recurrent ALK-negative anaplastic large cell lymphoma presenting as ulcerating skin lesion."}, {"pubmed": 23307059, "text": "Report subtype-specific incidence of ALK immunoreactivity in rhabdomyosarcomas and showed the association between ALK expression and several clinicopathologic/molecular parameters."}, {"pubmed": 23335077, "text": "MET and ALK may have roles in poor survival in Ewing sarcoma"}, {"pubmed": 23338972, "text": "Our investigation of the mechanisms underlying the decrease in miR-26a in this lymphoma revealed novel evidence that STAT3, a major downstream substrate of NPM-ALK tyrosine kinase activity, suppresses MIR26A1 gene expression."}, {"pubmed": 23341890, "text": "The prevalence of EML4-ALK, EGFR status and KRAS mutations in 208 Chinese patients with non-small cell lung cancer, is reported."}, {"pubmed": 23344087, "text": "ALK rearrangement is associated with crizotinib resistance in non-small-cell lung cancer."}, {"pubmed": 23360421, "text": "Patients showing high ALK and low Shf mRNA expressions showed poor prognosis."}, {"pubmed": 23379755, "text": "The prevalence of ALK translocation in an unselected population of European patients with advanced non-small-cell lung carcinomas was 10%."}, {"pubmed": 23401436, "text": "Anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positive cancers are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib."}, {"pubmed": 23407557, "text": "ALK protein overexpression and ALK gene rearrangement is associated with lung adenocarcinomas."}, {"pubmed": 23407559, "text": "ALK gene rearrangement is associated with non-small-cell lung cancer."}, {"pubmed": 23434628, "text": "The new multiplex deep sequencing method is capable to quickly detect resistance mutations within the ALK kinase domain from tumor biopsies."}, {"pubmed": 23453647, "text": "ALK translocations appear to be constant between primary tumors and BM, amplifications seem to be more prevalent in BM. ALK translocation, but not ALK amplification is associated with ALK protein overexpression."}, {"pubmed": 23484153, "text": "Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods."}, {"pubmed": 23486271, "text": "ALK rearrangement is associated with response to therapy in non-small-cell lung cancer."}, {"pubmed": 23490651, "text": "Data indicate that anaplastic lymphoma kinase (ALK) translocations are not present in oesophageal cancer, ALK amplifications are common events with comparable rates in cell carcinoma (SCC) and adenocarcinoma (AC)."}, {"pubmed": 23495083, "text": "ALK gene rearrangement is associated with metastatic lung adenocarcinoma."}, {"pubmed": 23523007, "text": "Detection of ALK rearrangement using ICC on routine Papanicolau cytology slides is considered to be advantageous for lung cancer treatments."}, {"pubmed": 23536384, "text": "ALK gene rearrangement is associated with lung adenocarcinoma."}, {"pubmed": 23561259, "text": "It is a promising candidate for a therapeutic target as well as for a diagnostic molecular marker in NSCLC."}, {"pubmed": 23568951, "text": "SCC4 treatment with demethylating agents induced ALK expression."}, {"pubmed": 23574788, "text": "the anaplastic lymphoma kinase protein was detected with high frequency in Merkel cell carcinomas"}, {"pubmed": 23617826, "text": "ALK rearrangement is associated with early pneumothorax as a feature of response to crizotinib therapy in lung adenocarcinoma."}, {"pubmed": 23625156, "text": "ALK rearrangement and EML4-ALK variation is associated with lung adenocarcinoma."}, {"pubmed": 23639470, "text": "ALK gene rearrangment is associated with advanced non-small-cell lung cancer."}, {"pubmed": 23661334, "text": "Profiling of 100 non-small cell lung cancers identified numerous genetic alterations impacting fibroblast growth factor receptor 3 (FGFR3) in lung squamous cell carcinoma and a novel ALK fusion partner in lung adenocarcinoma."}, {"pubmed": 23664096, "text": "Results indicate rare overexpression of anaplastic lymphoma kinase (ALK) mRNA in 4% of cases of inflammatory breast cancer (IBC) and in 2% of non-IBC samples."}, {"pubmed": 23664446, "text": "The first report concerning the presence of the EML4-ALK fusion gene in a sarcomatoid carcinoma of the lung."}, {"pubmed": 23669200, "text": "ALK-break negative NSCLC cases revealed concordant homogeneous results by means of FISH."}, {"pubmed": 23669222, "text": "Data suggest that using circulating tumor cells (CTCs) harboring a unique ALK rearrangement and mesenchymal phenotype may arise from clonal selection of tumor cells."}, {"pubmed": 23683537, "text": "Whose tumor had EGFR and ALK genetic aberration."}, {"pubmed": 23716548, "text": "Non-common type anplastic lymphoma kinase-positive anaplastic large cell lymphomas express CD8 more frequently than common type."}, {"pubmed": 23729361, "text": "Functional ALK rearrangements were mutually exclusive with EGFR and KRAS mutations in a large Western patient population. This lack of overlap was also observed in ALK-positive cancers with acquired resistance to crizotinib"}, {"pubmed": 23730215, "text": "Dual mutation of Tyr644 and Tyr664 in Nucleophosmin-anaplastic lymphoma kinase(NPM-ALK)abrogates its physical association with IGF-IR."}, {"pubmed": 23743932, "text": "Chromogenic in situ hybridization is a highly reliable, sensitive and specific method for the detection of ALK gene rearrangements in pulmonary adenocarcinomas."}, {"pubmed": 23751074, "text": "The anaplastic lymphoma kinase (ALK) break points in acral/mucosal melanomas, were investigated."}, {"pubmed": 23769207, "text": "Use of crizotinib to treat patients with advanced, ALK-positive NSCLC."}, {"pubmed": 23774148, "text": "We have demonstrated that FISH testing for ALK can be performed simultaneously with other diagnostic procedures, providing oncologists with results in a timely manner to make informed decisions about patient treatment."}, {"pubmed": 23777859, "text": "Ligand independent activation of anaplastic lymphoma kinase (ALK) results when the cytokine pleiotrophin (PTN) interacts with its receptor, the receptor protein tyrosine phosphatase beta-zeta (RPTPbeta-zeta). Review)"}, {"pubmed": 23797004, "text": "ALK positivity in neuroblastic tumors correlated with advanced tumor types"}, {"pubmed": 23814019, "text": "NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming has a role in anaplastic large cell lymphoma"}, {"pubmed": 23851431, "text": "Data indicate that anaplastic lymphoma kinase (ALK) expression is uncommon in both pancreatic ductal adenocarcinoma and neuroendocrine tumors, and that ALK is not induced by translocation, and is unlikely to be a therapeutic target."}, {"pubmed": 23867124, "text": "Report co-expression of IGF-1R and ALK in embryonal and alveolar rhabdomyosarcoma and suggest both as possible drug targets."}, {"pubmed": 23887300, "text": "EML4-ALK gene rearrangements do not appear to be involved in the development of primary adenocarcinoma of the urinary bladder."}, {"pubmed": 23919423, "text": "evaluated mutations in four driver genes, epidermal growth factor receptor (EGFR), Kirsten ras oncogene (KRAS), c-MET, and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), in Chinese lung adenocarcinoma patients"}, {"pubmed": 23922356, "text": "ALK protein expression is statistically associated with alveolar rhabdomyosarcoma histology, metastatic disease at diagnosis and primary trunk site"}, {"pubmed": 23922677, "text": "44 cases of ALK-rearranged samples were identified by fluorescent in-situ hybridization (FISH), immunohistochemistry (IHC), and reverse transcription polymerase chain reaction (RT-PCR) in a large number of surgically resected lung cancers"}, {"pubmed": 23932486, "text": "The frequencies of somatic EGFR, KRAS, and ALK gene abnormalities reflect the diverse ethnicity and smoking patterns of non-small-cell lung cancers patients in the United States."}, {"pubmed": 23951022, "text": "Data indicate that all of the 8 patients with high abundance of Echinoderm microtubule-associated protein-like 4- anaplastic lymphoma kinase (EML4-ALK) positive cells in tumor tissues were also have high expression of ALK protein."}, {"pubmed": 23975180, "text": "STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma."}, {"pubmed": 23988776, "text": "in lung adenocarcinomas, KRAS mutations are prevalent in male smokers; EGFR mutations are associated with female sex, nonsmoking and lepidic and micropapillary growth; TTF1 has a role in survival; BRAF mutations have roles in survival"}, {"pubmed": 23991058, "text": "Data indicate that expression of several predicted chimeric genes and genes with disrupted exon structure including ALK, NBAS, FHIT, PTPRD and ODZ4 in neuroblastoma."}, {"pubmed": 24060861, "text": "ALK activation in cancer can arise from translocations creating oncogenic fusion proteins or through overexpression & mutation of full-length ALK. Review."}, {"pubmed": 24129244, "text": "A potential role of targeting ALK in advanced colorectal carcinomas by using ALK FISH and ALK immunohistochemistry as a screening tool to detect ALK alterations."}, {"pubmed": 24149177, "text": "Quantitative assessment of ALK mRNA expression helps to improve risk stratification of rhabdomyosarcoma patients and identifies tumours with adverse biological characteristics and aggressive behaviour."}, {"pubmed": 24192124, "text": "EGFR mutation as well as KRAS and ALK rearrangements are important biomarkers in the field owing to potential targeted therapies involved in clinical practice"}, {"pubmed": 24200637, "text": "Data indicate that coexistence of EML4-ALK fusion or ALK copy number increase and EGFR, MET, and KRAS mutations in tumor tissue from two treatment-naive Chinese non-small cell lung cancer (NSCLC) patients."}, {"pubmed": 24218456, "text": "Activity of NPM/ALK chimeric protein closely resembles cell activation induced by IL-2. 67% of the affected genes were modulated in common by NPM/ALK & IL-2, especially those involved in Jak/STAT- & IL-2-signaling pathways."}, {"pubmed": 24228132, "text": "Case Report: anaplastic lymphoma kinase-positive large B-cell lymphoma diagnosed using cytological features of the pleural effusion."}, {"pubmed": 24276038, "text": "ALK copy number gain is associated with metachronous neuroblastoma."}, {"pubmed": 24277751, "text": "This case suggests that echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion is an oncogenic event in not only carcinomas but also sarcomas originating from stromal cells."}, {"pubmed": 24288180, "text": "Crizotinib is the standard of care in terms of the treatment of patients with ALK-positive, advanced NSCLC."}, {"pubmed": 24293609, "text": "Chromogenic in situ hybridisation is a very reliable, convenient and inexpensive method to detect ALK-positive non-small cell lung carcinomas."}, {"pubmed": 24300132, "text": "gene rearrangement has no prognostic relevance in patients with resected non-small cell lung cancer"}, {"pubmed": 24346098, "text": "EML4-ALK fusion is uncommon, reported in about 5% of NSCLC patients."}, {"pubmed": 24356251, "text": "ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma"}, {"pubmed": 24388371, "text": "EML4-ALK fusion genepositivitymightbe higher inyoungerNSCLCpatientswithwild-type EGFR."}, {"pubmed": 24389440, "text": "ALK gene rearrangement is associated with spinal cord metastasis and leptomeningeal carcinomatosis in non-small-cell lung cancer."}, {"pubmed": 24389444, "text": "Increased ALK gene copy number is associated with response to chemotherapy in lung adenocarcinoma."}, {"pubmed": 24389446, "text": "ALK 2p23 fusion and rearrangement is associated with response to chemotherapy in Choroidal metastases."}, {"pubmed": 24389447, "text": "ALK rearrangement is associated with response to chemotherapy in brain metastases of non-small-cell lung cancer."}, {"pubmed": 24403104, "text": "ALK-positive patients have a good response to first-line cytotoxic drugs and to crizotinib as second-line therapy, but a relatively poor response to cytotoxic drugs as second-line therapy."}, {"pubmed": 24415871, "text": "ALK copy number gain is present in hepatocellular carcinoma and may be an unfavorable prognostic predictor."}, {"pubmed": 24419060, "text": "Findings indicate that ASP3026 has potential efficacy for non-small cell lung cancer (NSCLC) and is expected to improve the therapeutic outcomes of patients with cancer with anaplastic lymphoma receptor tyrosine kinase (ALK) abnormality."}, {"pubmed": 24419423, "text": "ALK kinase splicing isoform is not associated with non-small-cell lung cancer."}, {"pubmed": 24442099, "text": "The ALK rearrangements are independently associated with younger age and the EGFR wild type. The EGFR mutations and the ALK rearrangements are rarely coexistent. The ALK rearrangements and the KRAS mutations are mutually exclusive."}, {"pubmed": 24443522, "text": "ALK rearrangements and EGFR mutations could coexist in a small subgroup of NSCLC."}, {"pubmed": 24462463, "text": "poorer disease-free survival in fusion-positive lung adenocarcinoma patients after curative surgery"}, {"pubmed": 24470379, "text": "analysis of the RANBP2-ALK gene fusion identified in ALK-positive diffuse large B-cell lymphoma with a unique nuclear membrane staining of ALK protein"}, {"pubmed": 24475247, "text": "A recurrent STRN/ALK fusion found in thyroid carcinomas."}, {"pubmed": 24478382, "text": "Different levels of ALK expression can be found in various cancer types. ALK fusion is a rare event in human solid cancers."}, {"pubmed": 24495999, "text": "ALK rearrangement and transcriptional up-regulation is associated with non-small-cell lung cancers."}, {"pubmed": 24509625, "text": "Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma."}, {"pubmed": 24518086, "text": "ALK rearrangement is associated with non-small-cell lung cancers."}, {"pubmed": 24518095, "text": "ALK rearrangement is associated with crizotinib responsiveness in non-small-cell lung cancer."}, {"pubmed": 24613277, "text": "RANBP2-ALK fusion combined with monosomy 7 may be related to a unique clonal hematologic disorder of childhood and adolescence, characterized by myelomonocytic leukemia and a poor prognosis [case report/ review]"}, {"pubmed": 24613930, "text": "Our data demonstrate that STRN-ALK fusion occurs in a subset of patients with highly aggressive types of thyroid cancer and provide initial evidence suggesting that it may represent a therapeutic target for these patients."}, {"pubmed": 24629636, "text": "ALK, ROS1 and RET fusions are associated with pathological features of lung adenocarcinoma and are more prevalent in solid-predominant adenocarcinoma."}, {"pubmed": 24633422, "text": "ALK translocation is a therapeutiv target for the treatment of aggressive papillary cancer of the thyroid."}, {"pubmed": 24648382, "text": "Anaplastic lymphoma kinase gene rearrangements is associated with non-small cell lung cancer."}, {"pubmed": 24687827, "text": "Case Report: ALK-Rearranged anaplastic thyroid carcinoma treated with crizotinib."}, {"pubmed": 24691006, "text": "the outcome of 68 patients with advanced colorectal cancer and RAS, BRAF and PI3KCA status according to ALK gene status, is reported."}, {"pubmed": 24698962, "text": "Case Report: VCL-ALK gene fusion in renal cell carcinoma in patient with sickle cell trait."}, {"pubmed": 24698967, "text": "Spitz nevi/tumors with ALK rearrangement show a characteristic plexiform morphology and that ALK immunohistochemistry and FISH enable the accurate identification of this morphologic and genetic distinct subset of spitzoid neoplasms."}, {"pubmed": 24706829, "text": "Hsp90-sensitive EML4-ALK variants are exceptions to the rule that oncogenic fusion proteins involve breakpoints in disordered regions of both partners"}, {"pubmed": 24722154, "text": "Our study demonstrated for the first time that MET receptor expression, but not MET gene amplification, is significantly increased in ALK(+) NSCLC"}, {"pubmed": 24736067, "text": "ALK gene rearrangements are associated with lung cancer."}, {"pubmed": 24736079, "text": "ALK G1202R mutation confers high-level resistance to alectinib in ALK-rearranged non-small-cell lung cancer patients who progressed on crizotinib."}, {"pubmed": 24736082, "text": "TPR-ALK fusion is associated with lung adenocarcinoma."}, {"pubmed": 24750504, "text": "data argue against PDGFRB activation in association with ALK gene aberrations in metastatic NSCLC and seem to imply differential pathobiological roles of ALK alterations in lung cancer and lymphoma, possibly depending on different fusion partner genes."}, {"pubmed": 24775606, "text": "ALK translocation, occurring at a frequency of 6.8% in Chinese patients, defines a unique molecular subgroup of lung tumors."}, {"pubmed": 24778081, "text": "Our preliminary data exclude the utility of analysis of the ALK gene in malignant mesothelioma"}, {"pubmed": 24785465, "text": "Data indicate 2,4-diarylaminopyrimidine analogues as potent inhibitors against both wild-type and mutant anaplastic lymphoma kinase (ALK) kinases."}, {"pubmed": 24815447, "text": "ALK rearrangement is a prognostic factor of tumor recurrence in completely resected non-small cell lung cancer of any stage."}, {"pubmed": 24830726, "text": "Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association."}, {"pubmed": 24846683, "text": "This is the first report of ALK rearrangement in an octogenarian patient with pleomorphic carcinoma of the lung."}, {"pubmed": 24878018, "text": "identification of ALK rearrangements in non-small cell lung cancer"}, {"pubmed": 24885803, "text": "Of the 523 NSCLC specimens, 20 (3.8%) were positive for ALK rearrangement by FISH analysis. EGFR and KRAS mutations were identified in 70 (13.4%) and 124 (23.7%) of the 523 tumor samples, respectively."}, {"pubmed": 24885886, "text": "ALK rearrangement is rare in lung cancer with nodular ground-glass opacity, but is associated with advanced stage and larger tumor size, suggesting its association with aggressive progression of lung adenocarcinoma."}, {"pubmed": 24885982, "text": "ALK+ NSCLC has distinct characteristics at CT imaging that, when combined with clinical covariates, discriminate ALK+ from non-ALK tumors and can potentially identify patients with a shorter durable response to crizotinib."}, {"pubmed": 24888607, "text": "Simultaneous panel genotyping revealed more prevalent ALK rearrangements than reported in previous studies and their strong association with advanced stage irrespective of sex or smoking history."}, {"pubmed": 24894770, "text": "performed immunohistochemistry and fluorescence in situ hybridization on 73 ALK-negative anaplastic large cell lymphomas (ALCLs) and 32 ALK-positive ALCLs and evaluated the associations among pathology, genetics, and clinical outcome"}, {"pubmed": 24899136, "text": "ALK fusion-positive lung lesions were significantly smaller and had a lower tumor disappearance rate than ALK fusion-negative lesions when using high-resolution computed tomography."}, {"pubmed": 24935562, "text": "EGFR gene mutations and the EML4-ALK fusion gene were detected in 92 lung adenocarcinoma patients in China."}, {"pubmed": 24942490, "text": "ALK fusion is an infrequent alteration in Finnish non-small cell lung cancer patients."}, {"pubmed": 24947326, "text": "data strongly support a role for ALK-wt, in addition to ALK-F1174L and ALK-R1275Q, to confer in vitro and in vivo tumorigenic properties on neural crest progenitor cells"}, {"pubmed": 24952065, "text": "Report stable binding of crizotinib with the native-type ALK in comparison to the mutant, drug resistant type ALK."}, {"pubmed": 24952482, "text": "Results suggest that heat shock protein 90 (Hsp90) inhibitors may overcome ligand-triggered resistance in microtubule associated protein-like 4 (EML4)--anaplastic lymphoma kinase (ALK) lung cancer cells."}, {"pubmed": 24982409, "text": "NSCLC patients with the EML4-ALK fusion gene might be relatively insensitivite to cytotoxic chemotherapy."}, {"pubmed": 25017418, "text": "All other 94 cases showed no ALK expression."}, {"pubmed": 25028527, "text": "Letter/Case Report: lung adenocarcinoma where EML4-ALK gene rearrangement was missed by FISH techniques but detected using reverse transcriptase PCR."}, {"pubmed": 25071110, "text": "In neuroblastoma, subclonal ALK mutations can be present at diagnosis with subsequent clonal expansion at relapse."}, {"pubmed": 25083769, "text": "ALK genomic alterations are rare and probably without prognostic implications in UC."}, {"pubmed": 25144242, "text": "Results suggested that chromothripsis may be a mechanism of oncogenic rearrangement of EML4-ALK."}, {"pubmed": 25145835, "text": "findings uncover the oncogenic role of the JUNB/CD30 axis and its potential as therapeutic target in ALK+ ALCL."}, {"pubmed": 25193384, "text": "we uncovered an ALK-specific regulation of the hypoxia response across different ALK(+) tumor types and propose HIFs as a powerful specific therapeutic target in ALK-rearranged ALCL and NSCLC."}, {"pubmed": 25228534, "text": "study identified a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the non-small cell lung cancer patient who developed resistance to alectinib; both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs"}, {"pubmed": 25228590, "text": "Targeting mTORC1 in combination with ALK leads to enhanced antitumor efficacy and prolongs survival in mouse xenograft models of human neuroblastoma coexpressing ALKF1174L and MYCN."}, {"pubmed": 25270523, "text": "Anaplastic lymphoma kinase translocation was found in sarcomatoid carcinoma of the head and neck."}, {"pubmed": 25312988, "text": "ALK positive lung adenocarcinomas are more likely than EGFR mutant lung adenocarcinomas to be associated with larger volume, multifocal thoracic lymphadenopathy."}, {"pubmed": 25351247, "text": "The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma."}, {"pubmed": 25393795, "text": "ALK rearrangement was found in 35 patients (3.2%). Cytological samples (using either direct smears or cell blocks), were more frequently non-assessable than histological samples (69% versus 89%, respectively) (p < 0.001)."}, {"pubmed": 25393796, "text": "Two patients with non-small-cell lung cancer developed acquired resistance to alectinib with the presence of a mutation in amino acid residue 1171 located in the hydrophobic regulatory spine of the ALK kinase."}, {"pubmed": 25413595, "text": "Results show that gene rearrangement in ALK protein lead to gene fusion which results in benign fibrous histeocytoma"}, {"pubmed": 25421750, "text": "Study of anaplastic Large Cell Lymphoma resistant to ALK Inhibitor AP26113 identified point mutations in ALK kinase domain generating amino acid substitutions."}, {"pubmed": 25434695, "text": "These findings should assist clinicians in assessing the likelihood of EML4-ALK rearrangements and EGFR mutations and understanding their biological implications in NSCLC."}, {"pubmed": 25501013, "text": "We conclude that 2.2% of papillary thyroid carcinomas are ALK-translocated"}, {"pubmed": 25514802, "text": "Difficulties in ALK FISH signal interpretation might be bypassed using this detailed scoring system, which is highly reproducible, helps clarify borderline samples (according to split type)."}, {"pubmed": 25517749, "text": "ALK genomic status is a clinically important therapeutic stratification tool in neuroblastoma."}, {"pubmed": 25527510, "text": "Authors developed a system to detect rearrangement of ALK in a large group of Korean thyroid cancer patients. We screened 474 malignant or benign thyroid tumor cases to identify ALK fusions."}, {"pubmed": 25527865, "text": "ALK protein expression is not a rare molecular event in lung squamous cell carcinoma."}, {"pubmed": 25529354, "text": "detection of ALK rearrangement when tumor tissue is not available. The Ventana ALK IHC assay is an effective screening method for ALK rearrangement in MPE cell blocks from patients with advanced NSCLC, demonstrating high agreement with FISH results"}, {"pubmed": 25557162, "text": "ALK gene rearrangement is associated with lung adenocarcinomas."}, {"pubmed": 25575117, "text": "Adenocarcinomas with ALK rearrangement appeared as solid masses with lobulated margins at CT, were more likely to be associated with lymphangitic metastasis, advanced ln metastasis, and pleural/ pericardial metastasis than were tumors with EGFR mutations."}, {"pubmed": 25576649, "text": "ALK gene rearrangement is associated with non-small cell lung carcinoma."}, {"pubmed": 25577516, "text": "The ALK gene fuses with echinoderm microtubule-associated protein-like 4 in the majority of ALK-positive lung cancer cases."}, {"pubmed": 25596129, "text": "Western blot showed phosphorylation of ALK, ERK1/2, and STAT3 in cells transfected with TPM3-ALK. Coiled-coil structure of TPM3 contributes to the transforming ability of the TPM3-ALK fusion protein, and longer TPM3 region leads to higher dimer formation."}, {"pubmed": 25602801, "text": "In addition to ALK fusions previously described in other tumor types (NPM1-ALK, TPR-ALK), we identified 2 novel ALK fusions (CLIP1-ALK and GTF3C2-ALK) in our cohort of Spitz tumors"}, {"pubmed": 25605972, "text": "Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK."}, {"pubmed": 25652313, "text": "this study concludes that the novel mechanism would regulate the expression of ALK in neuroblastoma and that NeuroD1 should be significantly involved in neuroblastoma tumorigenesis."}, {"pubmed": 25674293, "text": "Case Report: ALK-positive ALCL displaying an unusual alveolar growth pattern."}, {"pubmed": 25682925, "text": "Brain metastases are frequent in advanced EGFR-mutated or ALK-rearranged non-small-cell lung cancers."}, {"pubmed": 25682942, "text": "ALK fusion with FN1 gene resulting in ALK overexpression is associated with inflammatory myofibroblastic tumor."}, {"pubmed": 25683346, "text": "ALK protein expression, phosphorylation, and genetic aberrations was measured by the FISH technique in 81 soft tissue tumor samples. ALK-phosphorylation-positive cases showed a statistically worse metastasis-free survival."}, {"pubmed": 25706305, "text": "It was revealed that the EML4-ALK fusion gene was observed predominantly in adenocarcinoma, non-smoking and non-small-cell lung cancers (NSCLC) patients, especially those diagnosed in the advanced clinical stage of NSCLC."}, {"pubmed": 25708242, "text": "ALK expression was correlated with ALK translocation, but not with ALK gene copy number gain. ALK translocation was also mutually exclusive with EGFR mutation in Taiwanese non-small cell lung cancer"}, {"pubmed": 25714698, "text": "Besides well-recognized ALK gene rearrangement, ALK gene amplification and mutations are common in many human cancers."}, {"pubmed": 25723109, "text": "inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions"}, {"pubmed": 25735977, "text": "H1299 NSCLC cells stably expressing EML4-ALK acquire epithelial-mesenchymal transition (EMT) phenotype, associated with enhanced invasive migration and increased expression of EMT-inducing transcription factors."}, {"pubmed": 25736571, "text": "ALK I1171 mutation confers resistance to alectinib."}, {"pubmed": 25740311, "text": "We have determined crystal structures of the coiled-coils from EML2 and EML4, which describe the structural basis of both EML self-association and oncogenic EML4-ALK activation."}, {"pubmed": 25757141, "text": "79 (69%) were negative for echinoderm microtubule-associated protein like 4 (EML4)-ALK translocation, nine (8%) were positive and 27 (23%) were unevaluable."}, {"pubmed": 25789833, "text": "Our findings show good correlation between FISH versus CISH in the detection of ALK and ROS1 rearrangements. FISH versus IHC showed good correlation in the detection of ALK rearrangements"}, {"pubmed": 25789835, "text": "The novel 1A4 antibody represents a promising candidate for screening lung tumors for the presence of ALK rearrangements."}, {"pubmed": 25795305, "text": "By combining karyotyping and RNA sequencing, we identified the 2 first ever reported anaplastic lymphoma kinase gene rearrangements in central nervous system tumors."}, {"pubmed": 25803816, "text": "This study shows a significant presence of ALK copy number gain in inflammatory breast cancer patients, and ALK copy number gain was associated with significantly poorer recurrence free survival."}, {"pubmed": 25813151, "text": "KRAS and EGFR co-mutation was detected in one case. PPMA patients with ALK rearrangements or KRAS mutation represent a unique subtype in Non-Small-Cell Lung Carcinoma"}, {"pubmed": 25813404, "text": "The combination of 2 different PCR tests is a viable approach for the diagnostics of ALK rearrangements."}, {"pubmed": 25855381, "text": "our findings indicate that LADCs with ALK, RET, and ROS1 fusions develop exclusively via their dependence on these oncogene fusions."}, {"pubmed": 25857825, "text": "the majority of epithelioid fibrous histiocytomas demonstrate ALK expression and ALK gene rearrangement. ALK expression is not seen in other variants of fibrous histiocytoma."}, {"pubmed": 25929957, "text": "analysis of anaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma"}, {"pubmed": 25964588, "text": "Such a complex diagnostic genetic profile has not been reported in ALK fusion-positive NSCLC. This case highlights the utility of comprehensive molecular testing in the diagnosis of NSCLC."}, {"pubmed": 25966792, "text": "Crizotinib was well tolerated and showed promising efficacy in Chinese patients with ALK-positive, advanced NSCLC."}, {"pubmed": 25967762, "text": "Immunohistochemistry performed on FNA smears using the cell transfer technique is an alternative method for the assessment of ALK rearrangement."}, {"pubmed": 25975837, "text": "ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2."}, {"pubmed": 26019170, "text": "We further showed that both EML4-ALK and mutant forms of EGFR modulate PD-L1 expression via common downstream pathways mediated by MEK-ERK and by PI3K-AKT."}, {"pubmed": 26032424, "text": "we propose that tumors harboring ALK mutations may be therapeutically tractable for personalized treatment of certain aggressive leukemias with ALK inhibitors."}, {"pubmed": 26045865, "text": "Case Report: lung adenocarcinoma with different histological types between primary tumor and metastasis, but both haboring ALK-rearrangement."}, {"pubmed": 26059187, "text": "These findings are of clinical importance given the potential role of ALK mutations in clonal evolution and relapse."}, {"pubmed": 26067621, "text": "Non-CpG methylation observed essentially in clinically favorable cases was associated with the differentiation status of neuroblastoma and expression of key genes such as ALK."}, {"pubmed": 26121314, "text": "Gene fusions involving the ALK gene occurs in epithelioid forms of benign fibrous histiocytoma."}, {"pubmed": 26147305, "text": "data, hence, provided evidences of a potentially active role of ALK in RMS cells, but also suggest caution in considering ALK a major therapeutic target in this malignancy"}, {"pubmed": 26152804, "text": "ALK and ROS1 rearrangements found in advanced non-small cell lung cancer patients"}, {"pubmed": 26172300, "text": "analysis of ALK rearrangement in colorectal adenocarcinoma by immunohistochemistry screening"}, {"pubmed": 26223379, "text": "Studies suggest that the presence of dual specificity phosphatase 22 (DUSP22) and p63 tumor suppressor protein (TP63) rearrangements might be useful to support a diagnosis of anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL)."}, {"pubmed": 26276782, "text": "anaplastic lymphoma kinase immunohistochemistry should be carried out to assess this diagnosis when spindle cell proliferations are observed"}, {"pubmed": 26295973, "text": "Anaplastic lymphoma kinase (ALK) rearrangements in medullary thyroid cancer."}, {"pubmed": 26299615, "text": "Suggest novel small molecule ALK inhibitors combined with RNA interfering based nanoliposomes in treatment of neuroblastomas."}, {"pubmed": 26314227, "text": "Cystic Brain Metastases Occurring in Anaplastic Lymphoma Kinase Gene Rearranged Non-Small-Cell Lung Cancer Patients Receiving Crizotinib."}, {"pubmed": 26338968, "text": "Results suggest that co-treatment with crizotinib and chloroquine could be beneficial for ALK-positive ALK-positive anaplastic large cell lymphoma patients."}, {"pubmed": 26379151, "text": "Report morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 gene rearrangements."}, {"pubmed": 26384210, "text": "ALK is overexpressed in a substantial proportion of breast cancers."}, {"pubmed": 26416997, "text": "Intratumoral genetic heterogeneity was demonstrated to coexist with histologic heterogeneity in both single-driver and ALK/EGFR coaltered lung adenocarcinomas (LADCs)."}, {"pubmed": 26418745, "text": "In conclusion, these data show that ALK is robustly activated by the FAM150A/B ligands."}, {"pubmed": 26422230, "text": "Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma"}, {"pubmed": 26444240, "text": "findings suggest a novel mechanism of oncogene activation in cancer through de novo alternative transcription initiation, such as for ALK"}, {"pubmed": 26454342, "text": "this study shows that anaplastic lymphoma kinase variants might have no correlation with clinical response to crizotinib in non-small-cell lung cancer patients"}, {"pubmed": 26505450, "text": "Data identified several cases of complex EGFR mutations, and concomitant EGFR mutations and ALK rearrangements in non-small cell lung cancer"}, {"pubmed": 26517679, "text": "Data show that inhibition of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK)-mediated stem-like properties enhances the anti-tumor effect."}, {"pubmed": 26537995, "text": "the discovery of EGFR mutations and ALK rearrangements has enabled the identification of patients who are more likely to benefit from a specific drug."}, {"pubmed": 26544515, "text": "Data suggest that platelets are a valuable source for the non-invasive detection of echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangements and for predicting and monitoring outcome to crizotinib."}, {"pubmed": 26555338, "text": "COPD-related NSCLC patients exhibited low prevalences of EGFR mutations and ALK rearrangements compared with the non-COPD group. Further studies are required regarding the molecular mechanisms underlying lung cancer associated with COPD"}, {"pubmed": 26568289, "text": "report the development of a structural analogue of alectinib (JH-VIII-157-02) that is potent against the G1202R Anaplastic Lymphoma Kinase mutant as well as a variety of other frequently observed mutants."}, {"pubmed": 26581482, "text": "Data show that 11/105 patients failed all molecular analysis: no mutations in oncogenes EGFR, KRAS and NRAS were detected, and no ALK gene rearrangements or MET gene amplifications were identified."}, {"pubmed": 26616860, "text": "Studies indicate that aberrant AXL receptor tyrosine kinase (AXL) signaling and development of an epithelial-to-mesenchymal transition (EMT) phenotype underlie resistance of anaplastic lymphoma kinase (ALK F1174L)-driven neuroblastoma (NB) cells to TAE684 and its derivatives."}, {"pubmed": 26618223, "text": "We will also provide a timely review on all ALK inhibitors and their current status of development in clinical settings"}, {"pubmed": 26630010, "text": "Data show FAM150B, which was named as augmentor-alpha (AUG-alpha), binds and activtes both anaplastic lymphoma kinase (ALK) and tyrosine kinase (LTK)."}, {"pubmed": 26657151, "text": "Data indicate that NPM-ALK was distributed in equal amounts between the cytoplasm and the nucleus."}, {"pubmed": 26687816, "text": "ALK activation in tumors was associated with favorable features, including a younger age at diagnosis, hyperdiploidy, and detection by mass screening"}, {"pubmed": 26704814, "text": "case report in which the EML4-ALK fusion gene was identified as a second primary lung cancer after surgically resecting EGFR mutation-positive adenocarcinoma"}, {"pubmed": 26719536, "text": "Rather than by secondary ALK mutations."}, {"pubmed": 26752677, "text": "ALK Rearrangement is associated with resistant to crizotinib therapy in a metastatic abdominal nodule with Small Cell Carcinoma."}, {"pubmed": 26755435, "text": "This review describes the biology of EML4 and ALK, explains the main features of EML4-ALK fusion proteins and outline the therapies that target EML4-ALK in cancer.  [review]"}, {"pubmed": 26758803, "text": "The docking results revealed that ligand interaction with Met 1199 plays a crucial role in binding of inhibitors to ALK"}, {"pubmed": 26781614, "text": "Given that the ALK immunohistochemical staining pattern is associated with the ALK fusion partner, the present results suggest that the prognosis for ALK positive large B-cell lymphoma differs depending on the ALK fusion partner."}, {"pubmed": 26789109, "text": "ALK rearrangements are associated with non-small-cell lung cancer."}, {"pubmed": 26823889, "text": "Case Report: Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor."}, {"pubmed": 26825369, "text": "Meta-analysis: immunohistochemistry assay using D5F3 and 5A4 antibodies reliably detected NSCLC with ALK rearrangement and may be useful as a screening method to identify these tumors."}, {"pubmed": 26848800, "text": "we report 2 cases of renal cell carcinomas harboring a novel STRN-ALK fusion"}, {"pubmed": 26857243, "text": "TERT promoter mutation is an independent predictor for distant metastasis of thyroid neoplasms, but ALK testing is not useful for clinical decision-making in Korean patients with a high prevalence of the BRAF V600E mutation."}, {"pubmed": 26872010, "text": "ALK-positive melanomas predominantly expressed the recently described ALK isoform, ALK, which lacks the extracellular and transmembrane domains of wild-type ALK, consists primarily of the intracellular tyrosine kinase domain, and originates from an alternative transcriptional initiation site within the ALK gene"}, {"pubmed": 26886284, "text": "There is a high prevalence of ALK positivity in wild-type EGFR non-small cell lung cancer"}, {"pubmed": 26888425, "text": "suggested that patients with ALK rearrangements are more likely to be young, have EGFR wild-type, and more likely to exhibit mucus secretion, solid tumor growth, lymph node metastasis and pleural metastasis"}, {"pubmed": 26933125, "text": "Colorectal carcinoma harboring ALK fusions represent a rare aggressive subtype of colorectal carcinoma with distinct clinicopathologic features. This report provides the first clinical evidence that such patients may benefit from targeted monotherapy with ALK inhibitors."}, {"pubmed": 26945447, "text": "point out the importance of taking into account both histopathologic and ALK immunohistochemical features to interpret ALK fluorescence in situ hybridization analyses in inflammatory and necrotic tumors"}, {"pubmed": 26951079, "text": "Studies indicate the role of anaplastic lymphoma kinase (ALK) in malignant proliferation and as a valid drug target."}, {"pubmed": 26966027, "text": "Data show that anaplastic lymphoma kinase (ALKinhibitor ASP3026 was well tolerated with no treatment-related deaths."}, {"pubmed": 26973202, "text": "our study suggested that the prevalence of ALK, ROS1 and RET fusions is very rare in lung squamous cell carcinoma patients."}, {"pubmed": 26973324, "text": "The primary objective (to determine the maximum tolerated dose) has been reported previously. This updated analysis includes all patients with ALK-rearranged NSCLC given oral ceritinib at the recommended dose of 750 mg/day in the dose-escalation and expansion phases."}, {"pubmed": 26984109, "text": "While FISH techniques have been implemented to characterize this translocation for some time, the implementation of this testing is hampered by its broad use of resources. Immunohistochemical techniques to identify and screen for EML4-ALK translocations may play an important role in the near future. This consensus paper offers recommendations of the sequence and quality of the respective test approaches which are validate"}, {"pubmed": 26992209, "text": "ALK point mutations are associated lung cancer."}, {"pubmed": 26992917, "text": "overexpression of phospho-ALK and alternative receptor tyrosine kinases such as phospho-EGFR, phospho-HER3, and phospho-IGFR-1R was observed in both resistant cell lines. Additionally, NRG1, a ligand for HER3, is upregulated and responsible for resistance by activating the EGFR family pathways through the NRG1-HER3-EGFR axis."}, {"pubmed": 26993609, "text": "Anaplastic lymphoma kinase gene rearrangement is associated with non-small cell lung cancer."}, {"pubmed": 27009859, "text": "Mutation in ALK-fusion genes are associated with tyrosine kinase inhibitor resistance in lung cancer."}, {"pubmed": 27056998, "text": "Durable benefits with pemetrexed-based therapies in RET-rearranged lung cancers are comparable with ALK- and ROS1-rearranged lung cancers. When selecting therapies for patients with RET-rearranged lung cancers, pemetrexed-containing regimens should be considered."}, {"pubmed": 27060609, "text": "EML4-ALK rearrangement detection in malignant pleural effusions is a complementary method for EML4-ALK detection. VETANA and qRT-PCR are more appropriate for MPE detection. EML4-ALK rearrangement in pleural effusions has a predictive value for treatment."}, {"pubmed": 27119231, "text": "ALK oncogenic activity is involved in the regulation of an epithelial mesenchymal transition phenotype in a subset of non-small cell lung carcinomas by repression of the epithelial splicing regulatory protein 1."}, {"pubmed": 27132509, "text": "The EML4-ALK-mediated upregulation of HIF1alpha, HK2 and glycolytic metabolism was also highly active in vivo as demonstrated by fluorodeoxyglucose-positron emission tomography imaging of xenografts grown from EML4-ALK-positive NSCLC cells."}, {"pubmed": 27136744, "text": "For intra-hepatic cholangiocarcinomas (IHCC)patients, ROS1, ALK and c-MET expression levels have prognostic significance on clinical outcomes. Although this finding may require further validation, it has led to proposal of a new stratification or enriched biomarker for future phase III trial of anti-EGFR therapy in IHCC"}, {"pubmed": 27142166, "text": "ALK gene rearrangement is associated with pulmonary adenocarcinoma."}, {"pubmed": 27179218, "text": "the first evidence of an inherited ALK variant in the WNT type of medulloblastoma"}, {"pubmed": 27183864, "text": "ALK protein expression was absent in all cases of sinonasal adenocarcinoma nor was chromosome 2 translocated, suggesting that ALK is not involved in this cancer."}, {"pubmed": 27225694, "text": "NSCLCs harboring EGFR mutations or ALK rearrangements are associated with low ORRs to PD-1/PD-L1 inhibitors. Low rates of concurrent PD-L1 expression and CD8(+) TILs within the tumor microenvironment may underlie these clinical observations."}, {"pubmed": 27249714, "text": "or patients with non-small cell lung cancer with a EGFR mutation and an anaplastic lymphoma kinase mutation(ALK) with brain metastases, several agents have shown intracranial activity. Lapatinib has been tested for patients with brain metastases from breast cancer harboring a HER2 mutation. molecular targeted therapies have shown efficacy in BRAF-positive melanoma brain metastasis"}, {"pubmed": 27262592, "text": "despite the marginal occurrence of ALK gene amplification/high polisomy, we did not observed any ALK, MET and ROS deregulation in sarcomatoid carcinoma of head and neck"}, {"pubmed": 27266545, "text": "Ventana immunohistochemistry, quantitative real-time reverse transcription-polymerase chain reaction and IHC testing plus fluorescent in situ hybridization confirmation for anaplastic lymphoma kinase testing following crizotinib treatment leaded to the incremental cost-effectiveness ratios"}, {"pubmed": 27271776, "text": "Aberrant ALK expression is observed in ovarian serous carcinoma but not in mucinous carcinoma, is independent of gene translocation, and might be associated with progression and prognosis."}, {"pubmed": 27318655, "text": "ALK Rearrangement is associated with Lung Cancer."}, {"pubmed": 27385213, "text": "data suggest a potential role of ALK in pediatric rhabdomyosarcoma"}, {"pubmed": 27401242, "text": "The ROS1 S1986Y/F and ALK C1156Y mutations are homologous and displayed similar sensitivity patterns to ALK/ROS1 TKIs."}, {"pubmed": 27413075, "text": "The treatment of patients with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive, metastatic non-small cell lung cancer."}, {"pubmed": 27418132, "text": "ALK-positive lung adenocarcinoma who test immunohistochemistry-positive and FISH-negative may still respond to crizotinib therapy."}, {"pubmed": 27432227, "text": "Results demonstrate that the frequency and spectrum of ALK resistance mutations differs depending on the ALK inhibitor. Moreover, resistance profiles may evolve over time and in response to sequential ALK inhibitors."}, {"pubmed": 27438515, "text": "ALK expression is therefore a helpful marker to distinguish EFH from cutaneous syncytial myoepithelioma"}, {"pubmed": 27460205, "text": "Ambiguous ALKpositive lung cancers are challenging tumors with diagnosis."}, {"pubmed": 27461700, "text": "These findings suggested that ALK can be considered as a promising target in the targeted therapy in patients with lung ADC."}, {"pubmed": 27469327, "text": "RT-PCR together with Sanger sequencing verified the presence of the FN1-ALK fusion transcripts"}, {"pubmed": 27490033, "text": "The results of our analysis indicate that C1156Y mutation alters the conformation of the ALK binding pocket residues which results in a marked decrease in hydrogen bond interactions between crizotinib and ALK."}, {"pubmed": 27496196, "text": "c-Met overexpression, HER-2 gene amplification, and SPTBN1-ALK gene fusion can coexist in lung adenocarcinoma and may become a potential biomarker of cancer refractory to crizotinib, chemotherapy, and radiotherapy as well as of a relatively poor prognosis."}, {"pubmed": 27507192, "text": "EML4-ALK Rearrangement Along with Resistance Mutation is associated with Lung Adenocarcinoma."}, {"pubmed": 27518729, "text": "Mutation in ALK gene is associated with Advanced Lung Adenocarcinoma."}, {"pubmed": 27526980, "text": "We report the first case of an ALK-positive Non Small Cell Lung Carcinoma patient who benefited from pemetrexed rechallenge after developing ALK inhibitor resistance. This strategy may be an option for some patients who suffer from acquired resistance to ALK inhibitors but responded to previous pemetrexed chemotherapy"}, {"pubmed": 27561692, "text": "A high ALK-gene copy number gain pattern might be associated with smoking status and theoretically it might mirror genomic instability in non-small lung cancer."}, {"pubmed": 27562706, "text": "ALK rearrangement was not observed in lung adenocarcinoma arising in long-term ex-smokers"}, {"pubmed": 27565907, "text": "Our results suggest that the ALK RGQ RT-PCR test could be useful in clinical practice as a complementary assay in multi-test diagnostic algorithms or even, if our data will be confirmed in independent studies, as a standalone or screening test for the selection of patients to be treated with ALK inhibitors."}, {"pubmed": 27565908, "text": "ALK kinase domain mutations seem to be uncommon events in ALK inhibitor-naive ALK rearranged lung adenocarcinomas but their effect on intrinsic resistance to achievable doses of clinically-available ALK inhibitors should be better evaluated in preclinical models and clinical cases."}, {"pubmed": 27604320, "text": "NLRR1 appears to be an extracellular negative regulator of ALK signalling in neuroblastoma and neuronal development."}, {"pubmed": 27609840, "text": "Alectinib (Alecensa; Roche/Genentech), a second-generation, orally active, potent, and highly selective inhibitor of anaplastic lymphoma kinase (ALK)."}, {"pubmed": 27612448, "text": "Case Report: primary small intestinal ALK positive anaplastic large cell lymphoma."}, {"pubmed": 27614248, "text": "ALK Fusion Patterns are associated with Response to Crizotinib Treatment in Lung cancer."}, {"pubmed": 27635639, "text": "The frequencies of ALK, ROS1 and RET rearrangements are low in non-adenocarcinoma NSCLC patients. And their clinical characteristics are similar to those in lung adenocarcinoma. Fusions of the above 3 genes are not prognostic factor for non-adnocarcinoma NSCLC patients."}, {"pubmed": 27637025, "text": "A majority of our ALK positive NSCLC patients were exposed to Crizotinib through the help of various support mechanisms and these patients had similar outcomes to that reported from previously published literature"}, {"pubmed": 27637426, "text": "This review summarizes the current understanding of the pathologic features, diagnostic approach, treatment options, resistance mechanisms, and future research areas for ALK-positive non-small cell lung cancer."}, {"pubmed": 27666124, "text": "EMT was reversed by miR200c, which suggests that miR200c may serve a role in mediating the sensitivity of NCI2228/CRI cells to crizotinib. The present study may therefore contribute to improving the sensitivity of ALK positive lung cancer cells to crizotinib"}, {"pubmed": 27707976, "text": "MYCN overexpression combined with activated anaplastic lymphoma kinase (ALK) is sufficient to induce neuroblastoma (NB) in mouse sympathoadrenal cells"}, {"pubmed": 27742657, "text": "Analysis of the residual, resected tumor identified a chromoplectic TPM3-ALK rearrangement that involved many other known oncogenes and was confirmed by rtPCR."}, {"pubmed": 27756333, "text": "The aim was to investigate the prevalence of ALK fusion variants and to compare clinical outcomes according to ALK fusion variants."}, {"pubmed": 27769042, "text": "ALK fluorescence in situ hybridization alone may not be the most reliable assay for detection of ALK gene rearrangements, and probably should be used in parallel with ALK immunohistochemistry and next generation sequencing for detection of gene fusions and mutations in lung adenocarcinoma."}, {"pubmed": 27776007, "text": "ALK gene fusion in spitzoid neoplasms results in tumors with a large diameter (>/=9 mm) and wedge-shaped, plexiform dermal architecture of nests of large, spindle-shaped cells ."}, {"pubmed": 27776643, "text": "ALK fusions occur in approximately 5% of lung adenocarcinoma and typically occur in a mutually exclusive manner to EGFR mutations."}, {"pubmed": 27780853, "text": "The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses."}, {"pubmed": 27811184, "text": "Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors"}, {"pubmed": 27840423, "text": "study describes a novel EEF1G-ALK gene fusion in 2 pediatric patients with anaplastic large cell lymphoma that is associated with a cytoplasmic-restricted localization of the ALK fusion protein"}, {"pubmed": 27879258, "text": "Nucleophosmin-anaplastic lymphoma kinase serves as the founding member of the ALK fusion protein family, and its role in malignant cell transformation is by far the best characterized and, thus, is the main focus of this review. [review]"}, {"pubmed": 27888620, "text": "clonal evolution of ALK mutations associated with neuroblastoma progression."}, {"pubmed": 27913214, "text": "ALK gene Rearrangement is associated with Venous Thromboembolism in Non-Small-Cell Lung Cancer."}, {"pubmed": 27943404, "text": "We assessed the prevalence of EML4-ALK rearrangement gene measured by immunohistochemistry in an unselected population-based consecutive cohort of patients with adenocarcinoma of the lung (ACL), and the correlation with smoking history, thyroid transcription factor 1 (TTF1), gender and age"}, {"pubmed": 27974674, "text": "Combining measurements of sweyjawbu expression and the ratio of the 5' and 3' portions of the ALK transcript provided accurate identification of ALK rearrangement-positive lymphomas."}, {"pubmed": 27986745, "text": "The combination of ribociclib, a dual inhibitor of cyclin-dependent kinase (CDK) 4 and 6, and the ALK inhibitor ceritinib demonstrated higher cytotoxicity and synergy scores (P = 0.006) in cell lines with ALK mutations as compared with cell lines lacking mutations or alterations in ALK ."}, {"pubmed": 27997549, "text": "ALK was the most commonly mutated gene in this cohort, and we observed a higher frequency of suspected oncogenic ALK mutations in relapsed disease than at diagnosis."}, {"pubmed": 28009326, "text": "ALK gene copy number gains occurred most due to unspecific polyploidy (whole DNA reduplication) rather than locus specific gene amplification in lung cancer."}, {"pubmed": 28030793, "text": "ALK-L1198F and ALK-G1201E mutations, originally identified in anaplastic thyroid cancer, do not result in ligand independent gain-of-function activity."}, {"pubmed": 28032602, "text": "Report accurate detect ALK gene rearrangements which could be used for diagnostic screening of lung cancer patients."}, {"pubmed": 28035073, "text": "microRNA expression profiles had clinicopathological implications that were related to EGFR and KRAS mutations, as well as ALK-rearrangement in lung adenocarcinoma."}, {"pubmed": 28039177, "text": "Our findings show that group EML4-ALK variants 3a/b in non-small cell lung cancer may be a major source of ALK inhibitor resistance in the clinic."}, {"pubmed": 28181564, "text": "the results from three transcriptome-based platforms (Nanostring Elements, Agena LungFusion panel and ThermoFisher NGS fusion panel) were compared to those obtained from ALK, ROS1 and RET Fluorescence In Situ Hybridization on 51 clinical specimens."}, {"pubmed": 28183714, "text": "Our data strongly suggest adapting the guidelines and using dichotomous ALK-IHC as standard companion diagnostic test to select patients with NSCLC who benefit from ALK-targeting therapy"}, {"pubmed": 28193771, "text": "However, toxicity issues remain a problem for ceritinib, and another next-generation ALK inhibitor, alectinib, is more likely to become the drug of choice for untreated patients"}, {"pubmed": 28326957, "text": "This study identified that an increase in the ALK copy number is a frequent genetic alteration in poorly differentiated neuroblastoma."}, {"pubmed": 28332225, "text": "This computational investigation in-sighted the molecular factors involved in crizotinib resistance which enhanced in the identification of new ALK drugs that brings individualized medicine to treat ALK positive NSCLC patients with specific mutations."}, {"pubmed": 28338501, "text": "Results indicate that ALK expression, at both the RNA and the protein levels, is strongly associated with the WNT-activated type of tumors and therefore may serve as a useful marker for the detection of this type of medulloblastoma. Importantly, ALK protein expression alone is also an indicator of good prognosis for medulloblastoma patients."}, {"pubmed": 28359267, "text": "High ALK expression is associated with Merkel cell carcinoma."}, {"pubmed": 28362192, "text": "we reviewed the literature related to characteristics of metastatic ovarian malignancies that form from lung tumors, the utility of ALK inhibition for treating ALK-positive NSCLC, the molecular diagnosis of ALK rearrangement and the role of next generation sequencing for ALK rearrangement detection."}, {"pubmed": 28364271, "text": "Data suggest that ALK rearrangement in lung adenocarcinoma is associated with specific and distinct clinical-pathological characters compared to other genotypes."}, {"pubmed": 28368455, "text": "Detection of the CAD-ALK gene fusion in urine tr-DNA anticipated radiological confirmation of disease progression. Analysis of plasma ctDNA identified ALK kinase mutations that emerged during treatment with the ALK inhibitor entrectinib"}, {"pubmed": 28370702, "text": "Knockdown of SMYD2 as well as treatment with a SMYD2 inhibitor in two NSCLC cell lines with an EML4-ALK gene significantly attenuated the phosphorylation levels of the EML4-ALK protein."}, {"pubmed": 28455243, "text": "ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells."}, {"pubmed": 28458126, "text": "The discovery of gain-of-function mutations in the ALK receptor tyrosine kinase gene as the major cause of familial neuroblastoma led to the discovery of identical somatic mutations and rapid advancement of ALK as a tractable therapeutic target. Inactivating mutations in a master regulator of neural crest development, PHOX2B, have also been identified in a subset of familial neuroblastomas."}, {"pubmed": 28461563, "text": "Our results suggest that the dynamic change in the numbers of circulating tumor cells (CTC) with ALK-CNG may be a predictive biomarker for crizotinib efficacy in ALK-rearranged non-small cell lung cancer (NSCLC)patients. Serial molecular analysis of CTC shows promise for real-time patient monitoring and clinical outcome prediction in this population."}, {"pubmed": 28504207, "text": "Case Report: inflammatory myofibroblastic tumor (IMT) of the urinary bladder with a novel HNRNPA1-ALK fusion."}, {"pubmed": 28546523, "text": "ALK protein expression was found in a significant number of patients and was correlated with advanced stage and high-risk neuroblastoma."}, {"pubmed": 28551680, "text": "Reverse transcription-polymerase chain reaction is a suitable method for detecting ALK translocations using cytology samples from patients with primary lung cancer."}, {"pubmed": 28557060, "text": "Among 718 patients with newly diagnosed metastasised non-squamous NSCLC, 12% (31/265) showed a positive test result for ALK rearrangements"}, {"pubmed": 28557340, "text": "TrkA plays an important role in the pathogenesis of NPM-ALK(+) T-cell lymphoma."}, {"pubmed": 28560674, "text": "Detection of Gene Rearrangements in Circulating Tumor Cells: Examples of ALK-, ROS1-, RET-Rearrangements in Non-Small-Cell Lung Cancer and ERG-Rearrangements in Prostate Cancer.("}, {"pubmed": 28561721, "text": "Recent preclinical models and translational efforts have provided critical insights into the molecular mechanisms of resistance to EGFR and ALK inhibitors. In this review, we present a framework for understanding resistance to targeted therapies. We also provide overviews of the molecular mechanisms of resistance and strategies to overcome resistance among EGFR-mutant and ALK-rearranged lung cancers"}, {"pubmed": 28589737, "text": "there are many treatment options for targeting ALK+ non-small-cell lung cancerbut the best treatment sequence remains unanswered"}, {"pubmed": 28601386, "text": "ALK and KRAS mutations are associated with acquired resistance to crizotinib in ALK-positive non-small cell lung cancer"}, {"pubmed": 28656214, "text": "the present study suggests that HER2 has an important role in the regulation of the cancer stem-like cells phenotype in ALK translocated lung cancers that is mainly orchestrated by HER2/HER3 heterodimers."}, {"pubmed": 28665943, "text": "ALK+, LBCL cases display a dismal clinical outcome and can only be cured with conventional chemotherapy protocols at the stage of localized disease"}, {"pubmed": 28705139, "text": "Detection of ALK expression by immunohistochemistry is reliable and the most practical way of identifying Non-small cell lung cancer patients likely to benefit from crizotinib treatment."}, {"pubmed": 28705706, "text": "Case Reports: inflammatory myofibroblastic tumors of the lung containing a chimeric A2M-ALK gene categorized as a specific type of inflammatory myofibroblastic tumor that develops exclusively in neonates and infants."}, {"pubmed": 28720066, "text": "High expression of SLC34A2 was identified in about 2/3 patients and correlated with significantly better patient's overall survival. Epidermal growth factor receptor mutations were detected in about 53% of patients with no statistically significant difference to patient's overall survival. Anaplastic lymphoma kinase rearrangement was found in 8 out of 175 patients, harboring this abnormality leads to shorter overall survi"}, {"pubmed": 28743163, "text": "Studies suggest that the routine clinical use of fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC) may be replaced by emerging next-generation sequencing and digital, color-coded barcode technologies, which have the advantage of simultaneously evaluating anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) and epidermal growth factor receptor (EGFR) alterations in a single analysis."}, {"pubmed": 28756644, "text": "Studies showed recurrent oncogenic alterations suche as chromosomal translocation and gene amplification of ALK in anaplastic large-cell lymphoma, inflammatory myofibroblastic tumor, and neuroblastoma and has highlighted the importance for ALK in histologically diverse pediatric cancers. [review]"}, {"pubmed": 28762087, "text": "The results of this real-life analysis suggest that the prognosis of NSCLC patients with theALK translocation may be better than that of the overall NSCLC population, but the outcomes were poorer than those of ALK+ NSCLC patients included in clinical studies."}, {"pubmed": 28910456, "text": "Unique ALK rearrangements in a subset of patients with peritoneal mesothelioma, each lacking asbestos fibers, therapeutic radiation, and cytogenetic and molecular alterations typically found in these tumors. Identification of clinically actionable ALK rearrangements may represent a novel pathogenetic mechanism of malignant peritoneal mesothelioma with promise for targeted therapy."}, {"pubmed": 28970558, "text": "Novel oncogenic ALK fusion transcripts have been found in non-small cell lung cancer patients using next-generation sequencing approaches."}, {"pubmed": 28987389, "text": "Results show no apparent association between environmental tobacco smoke exposure and ALK translocation."}, {"pubmed": 29046324, "text": "The prevalence of STRN-ALK kinase fusions were determined in papillary thyroid cancer of an adult population"}, {"pubmed": 29048652, "text": "Our data suggest that targeting Src signaling may be an effective approach to the treatment of ALK-non-small cell lung cancer (NSCLC) with acquired resistance to ALK inhibitors."}, {"pubmed": 29053547, "text": "Case Report: cutaneous anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma with linear distributional lesions and sarcomatoid histologic features."}, {"pubmed": 29079636, "text": "Patients whose tumors harbor ALK rearrangements or fusions respond to treatment with crizotinib and alectinib, including tumors not normally associated with ALK mutations, such as non-Langerhans cell histiocytosis or renal cell carcinoma. Comprehensive genomic profiling using next-generation sequencing can detect targetable ALK fusions irrespective of tumor type or fusions partner"}, {"pubmed": 29093346, "text": "Results suggest that ALK generated by alternative transcription Initiation induces chromatin structural changes and heterochromatinization through phosphorylation of AKAP8 in the nucleus."}, {"pubmed": 29143897, "text": "In this review, we will discuss the current methods used in ALK rearrangement detection with emphasis on their key advantages and disadvantages."}, {"pubmed": 29150811, "text": "ALK expression has different prognostic significance in patients with Anaplastic large cell lymphomas."}, {"pubmed": 29184034, "text": "In xenografts in mice, trametinib inhibited the growth of EML4-ALK-positive non-small cell lung cancer and RAS-mutant neuroblastoma but not ALK-addicted neuroblastoma."}, {"pubmed": 29191580, "text": "status had a profound influence on the ALK-related prognosis of NSCLC. ALK rearrangement predicted a better prognosis in the general population with NSCLC, but a poor survival in the non-smoking population."}, {"pubmed": 29199678, "text": "Here, we report our experience with ceritinib in terms of its efficacy and safety among ALK-positive nonsmall cell lung cancer patients who were previously exposed to crizotinib."}, {"pubmed": 29199679, "text": "A negative ALK immunohistochemistry result obviates the need for a FISH test barring those with a strong clinical profile, and a positive ALK immunohistochemistry result is sufficient basis for the initiation of treatment."}, {"pubmed": 29199690, "text": "Mutation testing at diagnosis is feasible in the vast majority of patients with Stage IV adenocarcinoma of the lung. Patients with EGFR or EML4ALK mutation and those who received pemetrexed maintenance had better clinical outcomes."}, {"pubmed": 29199691, "text": "Our analysis indicated that ALK-EML4 positive non-small-cell lung cancers comprised a unique subgroup of adenocarcinomas with distinct clinicopathological characteristics. Incidence of ALK positivity was found to be higher in females and never smokers."}, {"pubmed": 29199692, "text": "Manual Immunohistochemistry is equally effective in the detection of ALK-rearranged cases as automated methods. It can be easily integrated as a screening method into routine practice thus reducing the cost of automated systems."}, {"pubmed": 29199696, "text": "Data from the initial studies revealed, EGFR mutations, and ALK gene rearrangements are mutually exclusive and as mutual causes of resistance to EGFR-TKIs or ALK-TKIs. However, this mutual exclusivity is being challenged with the increasing evidence showing the coexistence of both EGFR and ALK"}, {"pubmed": 29199697, "text": "We report higher frequency of ALK positivity (10.9%) in patients with adenocarcinoma of the lung. ALK by immunohistochemistry is more sensitive than FISH for ALK detection with high concordance. These patients had good clinical outcome with TKIs targeting ALK fusion protein."}, {"pubmed": 29251734, "text": "in 24 ALK+ lung adenocarcinoma cases, 15 rearrangements detected (gene partner: EML4 in all cases)"}, {"pubmed": 29317428, "text": "We describe a unique case in which a patient with ALK-rearranged adenocarcinoma underwent small-cell transformation at a metastatic site with retained ALK rearrangement and was provided clinical follow-up after treatment with second-generation tyrosine kinase inhibiter (TKI) therapy."}, {"pubmed": 29317532, "text": "activation of ALK/LTK family receptors by small ALKAL proteins (FAM150, AUG) conserved in vertebrates"}, {"pubmed": 29327716, "text": "This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer."}, {"pubmed": 29327718, "text": "This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain."}, {"pubmed": 29336091, "text": "The study reviews the drug-resistance mechanism of lung neoplasm cells with rearranged ALK. The resultant ALK fusion protein is aberrantly overexpressed and dimerized through the oligomerization domains, such as the coiled-coil domain, in the fusion partner that induces abnormal constitutive activation of ALK tyrosine kinase. Gene amplification or mutation confers tumor resistance to kinase inhibitors. [review]"}, {"pubmed": 29363116, "text": "EML4-ALK fusion variant V3 is a high-risk feature for anaplastic lymphoma kinase-driven non-small cell lung cancer"}, {"pubmed": 29370427, "text": "ALK gene Rearrangement is associated with Metastatic Colorectal Cancer."}, {"pubmed": 29413046, "text": "RNA-seq detects ALK rearrangements with a high sensitivity and specificity using only 10ng of RNA. It appears to be a promising rescue technique for non-clear-cut IHC/FISH cases and also offers a unique opportunity to identify ALK fusion variants."}, {"pubmed": 29451020, "text": "Brigatinib, a next-generation ALK inhibitor, shows promising activity in ALK-rearranged NSCLC that have previously received crizotinib with response rates in ALTA ranging from 42-50%, intracranial response 42-67% and median progression-free survival 9.2-12.9 months. Randomized Phase III trial, ALTA-1 L is investigating brigatinib in ALK inhibitor-naive patients"}, {"pubmed": 29455091, "text": "The method was successfully applied to a phase I clinical study of ALK-positive advanced NSCLC patients."}, {"pubmed": 29488330, "text": "In this paper, we reviewed fusion partner genes with ALK, detection methods for ALK-rearrangement (ALK-R), and the ALK-tyrosine kinase inhibitor, crizotinib, used in non-small-cell lung cancer patients."}, {"pubmed": 29517858, "text": "The EML4-ALK fusion gene may be a strong oncogene in younger patients with lung adenocarcinoma."}, {"pubmed": 29571990, "text": "this study describes response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants"}, {"pubmed": 29582563, "text": "Baseline Circulating tumor cell count could be a predictive biomarker for EGFR-mutated and ALK-rearranged non-small cell lung cancer , which allows for better guidance and monitoring of patients over the course of molecular targeted therapies."}, {"pubmed": 29623743, "text": "Study based on 47 tissue samples from spitzoid tumors revealed 2 BAP1-inactived cases. The absence of anomalous expression of translocation-related proteins ALK and ROS1 in this series, composed predominantly of low-grade/low-risk tumors, indicates that translocated spitzoid lesions may not be as prevalent as initially suggested, at least in some populations."}, {"pubmed": 29628502, "text": "The study reports a fusion circRNA (F-circEA) produced from the EML4-ALK fusion gene mainly located in the cytoplasm. Moreover, F-circEA, independent of the EML4-ALK linear transcript and fusion protein, can promote cell migration and invasion, thus contributing to tumor development."}, {"pubmed": 29635259, "text": "Case Reports: melanocytic myxoid spindle cell tumor with ALK gene rearrangement."}, {"pubmed": 29650534, "text": "Results suggest that sequential ALK inhibitors can foster the emergence of compound ALK mutations conferring high level resistance to lorlatinib in ALK-positive lung neoplasm."}, {"pubmed": 29723525, "text": "Anaplastic lymphoma kinase (ALK) is a novel regulator of NLRP3 inflammasome activation in macrophages. Mechanically, ALK-mediated NF-kappaB activation was required for the priming step of NLRP3 upregulation, whereas ALK-mediated lipid peroxidation contributed to the sensing step of NLRP3-NEK7 complex formation."}, {"pubmed": 29768721, "text": "the wild-type subgroup refers to EGFR negative/ALK negative, EGFR negative/ALK unknown, and EGFR unknown/ALK negative populations. Wild type and unknown subgroups were defined as EGFR negative/ALK negative, EGFR negative/ALK unknown, EGFR unknown/ALK negative, and EGFR unknown/ALK unknown populations. Adverse events (AEs) were recorded according to Common Terminology Criteria for Adverse Events version 4.0."}, {"pubmed": 29776956, "text": "Our findings suggest that high integrin b3 expression in ALK-rearranged non-small cell lung cancer (NSCLC) is associated with tumor progression and a worse prognosis. This finding demonstrates the prognostic value of integrin b3 and provides a rationale for combination treatment with ALK and integrin b3 inhibitors in patients with ALK-rearranged NSCLC."}, {"pubmed": 29885057, "text": "TP53 mutations define a subset of ALK-translocated non-small cell lung carcinoma tumours with recurrent MYC amplication that harbour chromosomal instability, leading to the co-occurrence of pathogenic aberrations."}, {"pubmed": 29923908, "text": "did identify ALK molecular changes and immunohistochemical staining patterns that have not been previously described in blue/cellular blue nevi or deep penetrating nevi"}, {"pubmed": 29938474, "text": "ALK Rearrangement is associated with lung Adenocarcinoma."}, {"pubmed": 30001233, "text": "Our results demonstrate that a subset of non-neural granular cell tumor harbor ALK fusions"}, {"pubmed": 30001602, "text": "The results further combined 3D-QSAR can not only profile the binding mechanism between the 2,4-Diarylaminopyrimidines inhibitors and ALK, but also supply the useful information for the rational design of a more potential small molecule inhibitor bound to ALK receptor."}, {"pubmed": 30006516, "text": "Study systematically explored the mutational effects of ALK mutations on non-small cell lung cancer drug resistance properties and found that the activation of ALK was increased by substitution with destabilizing mutations, creating the capacity to confer drug resistance to inhibitors."}, {"pubmed": 30015720, "text": "ALK is a highly specific diagnostic immunohistochemical marker for ALK fusion in uterine mesenchymal tumors."}, {"pubmed": 30037374, "text": "characteristics of the expression of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) in non-small cell lung cancer"}, {"pubmed": 30082557, "text": "Non-Small Cell Lung Cancers positive for ALK mutation by immunohistochemistry but not detected by Fluorescence in situ Hybridization show good response to crizotinib and merit treatment with the same"}, {"pubmed": 30107055, "text": "lung adenocarcinoma in Asian patients aged </=50 years had a higher gene mutation rate than in those aged >50 years, especially EML4-ALK and ROS1 fusion. Mutation analysis may be helpful in determining targeted therapy for the majority of these patients"}, {"pubmed": 30187817, "text": "here we identified a novel GORASP2-ALK rearrangement in a patient with ALK + LBCL with a unique ALK immunohistochemical staining pattern."}, {"pubmed": 30201068, "text": "Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer"}, {"pubmed": 30236141, "text": "a novel circRNA F-circEA-2a produced from the EML4-ALK fusion gene was identified and mainly located in the cytoplasm to promote cell migration and invasion in lung cancer cells."}, {"pubmed": 30348720, "text": "There were 35 patients with ALK-positive non-small cell lung cancer , nine of whom received ceritinib after alectinib. The overall response rate to ceritinib was 44%. It was 16% in patients who received ceritinib immediately after alectinib, and 100% in patients who received chemotherapy before ceritinib."}, {"pubmed": 30355843, "text": "The prevalence of ALK mutation rate in EGFR-negative NSCLC patients was 3.8% in a Bulgarian cohort."}, {"pubmed": 30429043, "text": "Patients with EGFR mutations or ALK rearrangements exhibited lower PD-L1 and CD8 co-expression level in TME."}, {"pubmed": 30476928, "text": "The frequency of ALK gene rearrangements in Latin America is similar to that previously reported from the Caucasian and Asian populations."}, {"pubmed": 30477470, "text": "C-Met overexpression co-exists with ALK rearrangement in a small population of advanced NSCLC. There may be a trend of favorable efficacy of crizotinib in such co-altered patients."}, {"pubmed": 30506595, "text": "For appropriate molecular testing of primary ALK (+) lung cancer."}, {"pubmed": 30523493, "text": "immunohistochemical detection of ALK protein is for investigation of identification and differentiation of WNT-activated medulloblastoma."}, {"pubmed": 30538293, "text": "Mutant ALK downregulates the 'HMG-box transcription factor 1' (HBP1)."}, {"pubmed": 30565433, "text": "ALK gene rearrangements are associated with non-small cell lung cancer."}, {"pubmed": 30572846, "text": "ALK ICC analysis on ThinPrep slides is a reliable ALK testing method, and the semiquantified interpretation system on cytology specimens is recommended rather than the binary scoring algorithm on tissue specimens."}, {"pubmed": 30573850, "text": "Report ALK-positive histiocytosis with frequent presence of KIF5B-ALK gene fusion."}, {"pubmed": 30580372, "text": "Females were often inflicted by the EGFR mutations, especially for the exon 19 deletion and L858R mutation. There were significantly more ALK/ROS1 fusions in females compared to that in males and significantly more ALK/ROS1 fusions in patients <60 years old compared to patients older than 60 years of age. Exon 21 L858R and L861Q dominantly occurred in patients >/=60 years and exon 19 deletion in patients <60 years"}, {"pubmed": 30591488, "text": "this is the first report of a KIF5B-ALK fusion gene in large-cell neuroendocrine carcinoma (LCNEC) . The patient was successfully treated with ALK inhibitors, suggesting that sensitivity to ALK inhibitor may define a specific LCNEC subtype. We propose that screening for ALK rearrangement in patients with LCNEC may assist in selecting potential candidates for targeted therapy."}, {"pubmed": 30599201, "text": "Patients with stage IV ALK-positive NSCLC can have prolonged OS. Brain metastases at diagnosis of stage IV disease does not influence OS."}, {"pubmed": 30658713, "text": "ALK-rearrangement can be detected in Circulating tumor cells collected from advanced non small cell lung cancer patients."}, {"pubmed": 30664791, "text": "Data suggest a mechanism by which SMAD4 protein (SMAD4) is inactivated in cancers and provides guidance for targeted therapies in anaplastic lymphoma kinase (ALK)-positive cancers."}, {"pubmed": 30688675, "text": "this study reveals 3.5% of ALK rearrangement rate in the cytology specimens from the patients with primary or metastatic lung non-small cell carcinoma"}, {"pubmed": 30706855, "text": "The incidence of both EGFR and ALK1 mutations is higher in the adenocarcinoma of the lung population studied and seem to correlate with a well differentiated, acinar pattern on morphology."}, {"pubmed": 30724750, "text": "Impact of Pre-Analytical Conditions on the Antigenicity of Lung Markers: ALK and MET."}, {"pubmed": 30790327, "text": "Immunohistochemical results revealed that ALK was expressed in 16 of 142 (11.3%) of SCLCs. The expression was focal and less intense, which is in contrast to strong and uniform expression in adenocarcinoma with ALK rearrangement."}, {"pubmed": 30791979, "text": "The study uncovered miR-100-5p to confer resistance to Crizotinib and Lorlatinib in EML4-ALK non-small cell lung cancer cells and to be a potential therapeutic target in drug resistance."}, {"pubmed": 30820854, "text": "Data suggest that the role of anaplastic lymphoma kinase (ALK)-mediated SMAD4 protein (Smad4) phosphorylation should be explored in late stages of cancer development where transforming growth factor beta (TGF-beta) can promote metastasis and colonization."}, {"pubmed": 30840206, "text": "ALK protein positivity may be more common in younger patients with NSCLC, especially those aged < 30 years, than in older patients. Among the histotypes, adenocarcinoma had the highest ALK protein-positive rate, whereas no ALK protein positivity was found in SCC."}, {"pubmed": 30843662, "text": "TP53 mutations, especially nondisruptive mutations, negatively affected the response to crizotinib and correlated with shorter PFS in ALK-rearranged NSCLC patients."}, {"pubmed": 30848386, "text": "It is crucial for the tumorigenesis and progression of neuroblastoma."}, {"pubmed": 30887601, "text": "Long noncoding RNA TM1P3 is involved in osteoarthritis by mediating chondrocyte extracellular matrix degradation."}, {"pubmed": 30943926, "text": "Findings suggest that the measurement of C-terminal ALK or ROS1 protein could be a reliable diagnostic method for each fusion in lung cancer."}, {"pubmed": 30946933, "text": "A novel heterogeneous nuclear ribonucleoprotein H3-ALK receptor tyrosine kinase rearrangement was found in one de novo salivary duct carcinoma"}, {"pubmed": 30955398, "text": "ALK and GD2 ganglioside are expressed in neuroblastoma; while GD2 immunostaining levels correlated with tumor differentiation and size, ALK immunostaining was not related to tumor differentiation or stage"}, {"pubmed": 31098955, "text": "ALK translocation can upregulate PD-L1 expression by activating ERK, STAT3 and AKT pathways."}, {"pubmed": 31177400, "text": "Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma."}, {"pubmed": 31215177, "text": "Results found ALK rearrangement not associated with survival of patients with lung adenocarcinoma."}, {"pubmed": 31226541, "text": "Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib."}, {"pubmed": 31364872, "text": "Efficacy of brigatinib in ALK+ non-small-cell lung cancer."}, {"pubmed": 31383960, "text": "A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation."}, {"pubmed": 31383967, "text": "PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma."}, {"pubmed": 31388026, "text": "Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity."}, {"pubmed": 31392269, "text": "Rearrangements of ALK/ROS1 were quantified using circulating tumor cells (CTCs) mRNA and matched with those identified in biopsy specimens from 12 patients with late-stage non-small cell lung cancer. Moreover, CTC counts and copy numbers of ALK/ROS1 rearrangements could be used together for evaluating treatment responses and disease progression."}, {"pubmed": 31431076, "text": "constitutively active ALK induces tumorigenic phenotypes, such as increased cancer cell proliferation/colony formation via YAP/TAZ and elevated immune evasion via YAP/TAZ-programmed death-ligand 1 in breast and lung cancer cells."}, {"pubmed": 31462708, "text": "ALK(ATI) interacted with c-Myc and increased the binding of c-Myc to the ABCG2 promoter, resulting in the induction of stem cell-like properties. Together, these findings indicate that ALK(ATI) may be a potential prognostic marker and therapeutic target for Soft tissue sarcoma (STS) patients harboring such ALK aberrations"}, {"pubmed": 31489711, "text": "Relationship between serum tumor markers and Anaplastic Lymphoma Kinase mutations in stage IV lung adenocarcinoma in Hubei province, Central China."}, {"pubmed": 31542727, "text": "A significant percentage of neuroblastoma tumours show high expression of anaplasticlymphoma kinase (ALK) or MYCN protein which was associated with adverse clinical prognostic factors."}, {"pubmed": 31558235, "text": "ALK-Rearranged Lung Adenocarcinoma is associated with Krukenberg Tumors."}, {"pubmed": 31677810, "text": "The incidence of ALK rearrangement-associated renal cell carcinomas is significantly lower in the Polish population."}, {"pubmed": 31707279, "text": "Positive ALK expression was found more frequently in younger patients (median age: 49 years), females (8.40%), never-smokers (8.82%), and those negative for carcinoembryonic antigen (CEA) (8.02%). Multivariate analysis demonstrated that younger age and never-smoker status were the only independent predictors of ALK."}, {"pubmed": 31711449, "text": "ALK rearrangements, and cMET amplifications were detected in 3.2, 5.3, and 2.1% of the cases, respectively. Concomitant mutations were detected only in a few cases."}, {"pubmed": 31734646, "text": "Study found that agonist-induced internalization of the dopamine D2 receptor (D2R) is regulated by the receptor tyrosine kinase ALK. Dopamine activated protein kinase C in an ALK-dependent manner and a PKC inhibitor blocked D2R internalization. Results indicate that ALK regulates D2R trafficking, which has implications for psychiatric disorders involving dysregulated dopamine signaling."}, {"pubmed": 31768065, "text": "In this study, we uncovered activating mutations in CSF1R and rearrangements in RET and ALK that conferred dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib, respectively, in patients with histiocytosis."}, {"pubmed": 31769228, "text": "Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations."}, {"pubmed": 31794146, "text": "Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma."}, {"pubmed": 31804622, "text": "The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma."}, {"pubmed": 31812932, "text": "Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches."}, {"pubmed": 31870845, "text": "Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors."}, {"pubmed": 31894386, "text": "Unique genetic characteristics were found in ALK-rearranged NSCLC patients with early disease onset, and these patients responded better to crizotinib and had longer PFS compared to patients with later disease onset."}, {"pubmed": 31900393, "text": "Combinatorial inhibition against both YAP1 and ALK provides a longer tumor remission in ALK-rearranged xenografts."}, {"pubmed": 31910789, "text": "The small numbers of KRAS mutations and ALK rearrangements are the limitation of this study for evaluation of diagnostic imaging. The frequency of these genetic alterations was as reported in the literature. We believe that our work will contribute to future meta-analysis."}, {"pubmed": 31937834, "text": "The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness."}, {"pubmed": 31955355, "text": "Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine."}, {"pubmed": 31961053, "text": "Resistance to ALK-TKI based on secondary mutation in this study was similar to that in previous reports."}, {"pubmed": 32020234, "text": "Identification of anaplastic lymphoma kinase fusions in clear cell renal cell carcinoma."}, {"pubmed": 32090101, "text": "Detection of ALK Gene Rearrangement in Cell-free RNA from Lung Cancer Malignant Pleural Effusion."}, {"pubmed": 32126881, "text": "Dual potent c-Met and ALK inhibitors: from common feature pharmacophore modeling to structure based virtual screening."}, {"pubmed": 32164629, "text": "Alteration in the sensitivity to crizotinib by Na(+)/H(+) exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers."}, {"pubmed": 32184261, "text": "EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7."}, {"pubmed": 32193476, "text": "Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein."}, {"pubmed": 32205481, "text": "Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene."}, {"pubmed": 32221155, "text": "Non-small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder."}, {"pubmed": 32224191, "text": "ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation."}, {"pubmed": 32271187, "text": "Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions."}, {"pubmed": 32312912, "text": "Oncogenic ALK (F1174L) drives tumorigenesis in cutaneous squamous cell carcinoma."}, {"pubmed": 32329859, "text": "The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors."}, {"pubmed": 32369239, "text": "Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis."}, {"pubmed": 32442405, "text": "Identification of ALK in Thinness."}, {"pubmed": 32460789, "text": "Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study."}, {"pubmed": 32467651, "text": "ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217."}, {"pubmed": 32484926, "text": "Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition."}, {"pubmed": 32540558, "text": "NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer."}, {"pubmed": 32563740, "text": "Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients."}, {"pubmed": 32564377, "text": "Correlation of novel ALK(ATI) with ALK immunohistochemistry and clinical outcomes in metastatic melanoma."}, {"pubmed": 32593262, "text": "[Epidemiology and diagnosis of mutations in the ALK gene in patients with non-small cell lung cancer in the Moscow region].\", trans \"Epidemiologiya i diagnostika mutatsii v gene ALK u patsientov s nemelkokletochnym rakom legkogo v Moskovskoi oblasti."}, {"pubmed": 32801121, "text": "Inhibition of Alk signaling promotes the induction of human salivary-gland-derived organoids."}, {"pubmed": 32804454, "text": "Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature."}, {"pubmed": 32815748, "text": "Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014."}, {"pubmed": 32822792, "text": "Systemic juvenile xanthogranuloma has a higher frequency of ALK translocations than BRAFV600E mutations."}, {"pubmed": 32833271, "text": "Double hit\"\" anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements."}, {"pubmed": 32876329, "text": "Clinicopathological and Prognostic Significance of the EML4-ALK Translocation and IGFR1, TTF1, Napsin A Expression in Patients with Lung Adenocarcinoma.\", trans \"Clinicopathological and Prognostic Significance of the EML4-ALK Translocation and IGFR1, TTF1, Napsin A Expression in Patients with Lung Adenocarcinoma."}, {"pubmed": 32881404, "text": "EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India."}, {"pubmed": 32928143, "text": "Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients."}, {"pubmed": 32930129, "text": "Concomitant echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in non-small cell lung cancer patients from eastern India."}, {"pubmed": 32966799, "text": "11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma."}, {"pubmed": 32979347, "text": "High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma."}, {"pubmed": 33034056, "text": "Identification of novel ALK rearrangements in gynecologic clear cell carcinoma."}, {"pubmed": 33038629, "text": "Functional coding/non-coding variants in EGFR, ROS1 and ALK genes and their role in liquid biopsy as a personalized therapy."}, {"pubmed": 33053439, "text": "Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma."}, {"pubmed": 33140567, "text": "The novel ALK inhibitor ZX-29 induces apoptosis through inhibiting ALK and inducing ROS-mediated endoplasmic reticulum stress in Karpas299 cells."}, {"pubmed": 33146791, "text": "Individualized nomogram for predicting ALK rearrangement status in lung adenocarcinoma patients."}, {"pubmed": 33161228, "text": "Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA."}, {"pubmed": 33168793, "text": "Comprehensive analysis of ALK, ROS1 and RET rearrangements in locally advanced rectal cancer."}, {"pubmed": 33237469, "text": "ALK alterations in salivary gland carcinomas."}, {"pubmed": 33248323, "text": "Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC."}, {"pubmed": 33255340, "text": "Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the EML4-ALK Transcript in H3122 Lung Cancer Cells."}, {"pubmed": 33273548, "text": "ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients."}, {"pubmed": 33290353, "text": "ALK Immunohistochemistry and Molecular Analysis in Uterine Inflammatory Myofibroblastic Tumor: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting."}, {"pubmed": 33310759, "text": "Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis."}, {"pubmed": 33387041, "text": "Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients."}, {"pubmed": 33399341, "text": "Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases."}, {"pubmed": 33402590, "text": "FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience."}, {"pubmed": 33452442, "text": "Aberrant role of ALK in tau proteinopathy through autophagosomal dysregulation."}, {"pubmed": 33486679, "text": "Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma."}, {"pubmed": 33563892, "text": "Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder."}, {"pubmed": 33583243, "text": "Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer."}, {"pubmed": 33637566, "text": "Activated ALK Cooperates with N-Myc via Wnt/beta-Catenin Signaling to Induce Neuroendocrine Prostate Cancer."}, {"pubmed": 33674381, "text": "Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation."}, {"pubmed": 33677892, "text": "[Clinicopathological significance in non-small cell lung cancer with mutations and co-mutations of EGFR, ALK and ROS1]."}, {"pubmed": 33683692, "text": "Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples."}, {"pubmed": 33707479, "text": "Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma."}, {"pubmed": 33712566, "text": "JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis."}, {"pubmed": 33761896, "text": "EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells."}, {"pubmed": 33818198, "text": "Two different patterns of lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement."}, {"pubmed": 33862316, "text": "CT radiomics-based prediction of anaplastic lymphoma kinase and epidermal growth factor receptor mutations in lung adenocarcinoma."}, {"pubmed": 33879893, "text": "[Semiquantitative parameters of (18)F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma]."}, {"pubmed": 34019866, "text": "Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients."}, {"pubmed": 34029351, "text": "ALK is frequently phosphorylated in Merkel cell carcinoma and associates with longer survival."}, {"pubmed": 34036223, "text": "Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors."}, {"pubmed": 34088997, "text": "Superficial ALK-rearranged myxoid spindle cell neoplasm: a cutaneous soft tissue tumor with distinctive morphology and immunophenotypic profile."}, {"pubmed": 34115544, "text": "Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)."}, {"pubmed": 34214505, "text": "Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma."}, {"pubmed": 34234236, "text": "SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy."}, {"pubmed": 34250410, "text": "Differential Impact of ALK Mutations in Neuroblastoma."}, {"pubmed": 34260934, "text": "Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration."}, {"pubmed": 34270745, "text": "Dermatan sulphate is an activating ligand of anaplastic lymphoma kinase."}, {"pubmed": 34273398, "text": "BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells."}, {"pubmed": 34310819, "text": "Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers."}, {"pubmed": 34322931, "text": "Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion."}, {"pubmed": 34378283, "text": "An unusual fusion gene EML4-ALK in a patient with congenital mesoblastic nephroma."}, {"pubmed": 34391065, "text": "Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance."}, {"pubmed": 34482333, "text": "Distinct Clinicopathologic Features and Possible Pathogenesis of Localized ALK-positive Histiocytosis of the Breast."}, {"pubmed": 34490727, "text": "A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients."}, {"pubmed": 34514573, "text": "Detection of ALK Gene Rearrangements in Non-Small Cell Lung Cancer by Immunocytochemistry and Fluorescence in Situ Hybridization on Cytologic Samples.\", trans \"Detection of ALK Gene Rearrangements in Non-Small Cell Lung Cancer by Immunocytochemistry and Fluorescence in Situ Hybridization on Cytologic Samples."}, {"pubmed": 34534615, "text": "Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer."}, {"pubmed": 34541785, "text": "Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review."}, {"pubmed": 34558414, "text": "Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma."}, {"pubmed": 34596344, "text": "Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma."}, {"pubmed": 34618040, "text": "Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data."}, {"pubmed": 34633654, "text": "F-circEA1 regulates cell proliferation and apoptosis through ALK downstream signaling pathway in non-small cell lung cancer."}, {"pubmed": 34646012, "text": "Structural basis of cytokine-mediated activation of ALK family receptors."}, {"pubmed": 34661367, "text": "Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation."}, {"pubmed": 34686712, "text": "Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement."}, {"pubmed": 34727172, "text": "ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition."}, {"pubmed": 34769149, "text": "Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer."}, {"pubmed": 34783600, "text": "The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis."}, {"pubmed": 34788123, "text": "Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer in the Middle East and North Africa."}, {"pubmed": 34819665, "text": "Structural basis for ligand reception by anaplastic lymphoma kinase."}, {"pubmed": 34819673, "text": "Mechanism for the activation of the anaplastic lymphoma kinase receptor."}, {"pubmed": 34843129, "text": "ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney."}, {"pubmed": 34861448, "text": "Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma."}, {"pubmed": 34948289, "text": "Activin A Promotes Osteoblastic Differentiation of Human Preosteoblasts through the ALK1-Smad1/5/9 Pathway."}, {"pubmed": 34957683, "text": "Mesothelioma with ALK gene mutations in two pediatric patients: Clinical course and outcome."}, {"pubmed": 35074700, "text": "Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!"}, {"pubmed": 35081265, "text": "Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions."}, {"pubmed": 35132576, "text": "ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma."}, {"pubmed": 35340157, "text": "[Relationship between EGFR, ALK Gene Mutation and Imaging and Pathological Features in Invasive Lung Adenocarcinoma]."}, {"pubmed": 35351152, "text": "The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer."}, {"pubmed": 35478149, "text": "ALK Protein Expression Patterns in Squamous Cell Carcinoma of the Oral Cavity."}, {"pubmed": 35486222, "text": "Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors."}, {"pubmed": 35514136, "text": "Impact of compound mutations I1171N + F1174I and I1171N + L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights."}, {"pubmed": 35624360, "text": "Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer."}, {"pubmed": 35665929, "text": "New evidence of genetic heterogeneity causing hereditary gingival fibromatosis and ALK and CD36 as new candidate genes."}, {"pubmed": 36029175, "text": "Loss of ALK hotspot mutations in relapsed neuroblastoma."}, {"pubmed": 36064579, "text": "ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3."}, {"pubmed": 36159860, "text": "Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation."}, {"pubmed": 36423218, "text": "Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer."}, {"pubmed": 36720638, "text": "Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia."}, {"pubmed": 36791109, "text": "ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression."}, {"pubmed": 36812383, "text": "ALK Gene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples."}, {"pubmed": 36866958, "text": "Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer."}, {"pubmed": 37126920, "text": "ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma."}, {"pubmed": 37271069, "text": "Expression of Anaplastic Lymphoma Kinase (ALK) in glioma and possible clinical correlations. A retrospective institutional study."}, {"pubmed": 37475109, "text": "Melanoma in infants, caused by a gene fusion involving the anaplastic lymphoma kinase (ALK)."}, {"pubmed": 37561984, "text": "Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults."}, {"pubmed": 37592266, "text": "Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma."}, {"pubmed": 37964559, "text": "Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity."}, {"pubmed": 38000524, "text": "The acetylation of STAT3 at K685 attenuates NPM-ALK-induced tumorigenesis."}, {"pubmed": 38128254, "text": "Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis."}, {"pubmed": 38307859, "text": "Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma."}, {"pubmed": 38451815, "text": "ALK upregulates POSTN and WNT signaling to drive neuroblastoma."}, {"pubmed": 38858548, "text": "Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growth."}, {"pubmed": 39103263, "text": "[ALK rearranged Spitz melanocytoma: a clinicopathological and molecular genetic analysis of two cases]."}], "genomic_pos": {"chr": "2", "end": 29921586, "ensemblgene": "ENSG00000171094", "start": 29192774, "strand": -1}, "genomic_pos_hg19": {"chr": "2", "end": 30144432, "start": 29415640, "strand": -1}, "go": {"BP": [{"evidence": "TAS", "gocategory": "BP", "id": "GO:0007165", "pubmed": 19459784, "qualifier": "involved_in", "term": "signal transduction"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0007169", "qualifier": "involved_in", "term": "cell surface receptor protein tyrosine kinase signaling pathway"}, {"evidence": "IDA", "gocategory": "BP", "id": "GO:0007169", "pubmed": [25605972, 30061385, 34646012], "qualifier": "involved_in", "term": "cell surface receptor protein tyrosine kinase signaling pathway"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0007275", "qualifier": "involved_in", "term": "multicellular organism development"}, {"evidence": "IDA", "gocategory": "BP", "id": "GO:0016310", "pubmed": 9174053, "qualifier": "involved_in", "term": "phosphorylation"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0021766", "qualifier": "involved_in", "term": "hippocampus development"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0030534", "qualifier": "involved_in", "term": "adult behavior"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0033674", "qualifier": "involved_in", "term": "positive regulation of kinase activity"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0036269", "qualifier": "involved_in", "term": "swimming behavior"}, {"evidence": "IDA", "gocategory": "BP", "id": "GO:0038083", "pubmed": [30061385, 34646012], "qualifier": "involved_in", "term": "peptidyl-tyrosine autophosphorylation"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0042127", "qualifier": "involved_in", "term": "regulation of cell population proliferation"}, {"evidence": "TAS", "gocategory": "BP", "id": "GO:0042981", "pubmed": 19459784, "qualifier": "involved_in", "term": "regulation of apoptotic process"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0045664", "qualifier": "involved_in", "term": "regulation of neuron differentiation"}, {"evidence": "IDA", "gocategory": "BP", "id": "GO:0046777", "pubmed": 9174053, "qualifier": "acts_upstream_of_or_within", "term": "protein autophosphorylation"}, {"evidence": "IDA", "gocategory": "BP", "id": "GO:0046777", "pubmed": 9174053, "qualifier": "involved_in", "term": "protein autophosphorylation"}, {"evidence": "TAS", "gocategory": "BP", "id": "GO:0046777", "pubmed": 19459784, "qualifier": "involved_in", "term": "protein autophosphorylation"}, {"evidence": "TAS", "gocategory": "BP", "id": "GO:0048666", "pubmed": 19459784, "qualifier": "involved_in", "term": "neuron development"}, {"evidence": "ISS", "gocategory": "BP", "id": "GO:0050995", "qualifier": "involved_in", "term": "negative regulation of lipid catabolic process"}, {"evidence": "TAS", "gocategory": "BP", "id": "GO:0051092", "pubmed": 19459784, "qualifier": "involved_in", "term": "positive regulation of NF-kappaB transcription factor activity"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0060159", "qualifier": "involved_in", "term": "regulation of dopamine receptor signaling pathway"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0090648", "qualifier": "involved_in", "term": "response to environmental enrichment"}, {"evidence": "ISS", "gocategory": "BP", "id": "GO:0097009", "qualifier": "involved_in", "term": "energy homeostasis"}, {"evidence": "ISS", "gocategory": "BP", "id": "GO:1900006", "qualifier": "involved_in", "term": "positive regulation of dendrite development"}], "CC": [{"evidence": "IBA", "gocategory": "CC", "id": "GO:0005886", "qualifier": "is_active_in", "term": "plasma membrane"}, {"evidence": "IDA", "gocategory": "CC", "id": "GO:0005886", "pubmed": [34646012, 34819673], "qualifier": "is_active_in", "term": "plasma membrane"}, {"evidence": "IDA", "gocategory": "CC", "id": "GO:0005886", "pubmed": 9174053, "qualifier": "located_in", "term": "plasma membrane"}, {"evidence": "TAS", "gocategory": "CC", "id": "GO:0005886", "pubmed": 19459784, "qualifier": "located_in", "term": "plasma membrane"}, {"evidence": "IDA", "gocategory": "CC", "id": "GO:0032991", "pubmed": 23382219, "qualifier": "part_of", "term": "protein-containing complex"}, {"evidence": "IBA", "gocategory": "CC", "id": "GO:0043235", "qualifier": "part_of", "term": "receptor complex"}, {"evidence": "HDA", "gocategory": "CC", "id": "GO:0070062", "pubmed": 19056867, "qualifier": "located_in", "term": "extracellular exosome"}], "MF": [{"category": "MF", "evidence": "IDA", "id": "GO:0004713", "pubmed": 9174053, "qualifier": "enables", "term": "protein tyrosine kinase activity"}, {"category": "MF", "evidence": "TAS", "id": "GO:0004713", "qualifier": "enables", "term": "protein tyrosine kinase activity"}, {"category": "MF", "evidence": "IBA", "id": "GO:0004714", "qualifier": "enables", "term": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "MF", "evidence": "IDA", "id": "GO:0004714", "pubmed": [9174053, 30061385, 34646012], "qualifier": "enables", "term": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "MF", "evidence": "TAS", "id": "GO:0004714", "pubmed": 19459784, "qualifier": "enables", "term": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "MF", "evidence": "IPI", "id": "GO:0005515", "pubmed": [17681947, 22939624, 26418745, 35384245], "qualifier": "enables", "term": "protein binding"}, {"category": "MF", "evidence": "IEA", "id": "GO:0005524", "qualifier": "enables", "term": "ATP binding"}, {"category": "MF", "evidence": "IDA", "id": "GO:0008201", "pubmed": [25605972, 34646012], "qualifier": "enables", "term": "heparin binding"}, {"category": "MF", "evidence": "IDA", "id": "GO:0030298", "pubmed": [30061385, 34646012], "qualifier": "enables", "term": "receptor signaling protein tyrosine kinase activator activity"}, {"category": "MF", "evidence": "IPI", "id": "GO:0042802", "pubmed": 25517749, "qualifier": "enables", "term": "identical protein binding"}]}, "homologene": {"genes": [[7955, 563509], [8364, 100495071], [9031, 421297], [9598, 459127], [9606, 238], [9615, 483021], [9913, 536642], [10090, 11682], [10116, 266802]], "id": 68387}, "interpro": [{"desc": "Protein kinase domain", "id": "IPR000719", "short_desc": "Prot_kinase_dom"}, {"desc": "MAM domain", "id": "IPR000998", "short_desc": "MAM_dom"}, {"desc": "Serine-threonine/tyrosine-protein kinase, catalytic domain", "id": "IPR001245", "short_desc": "Ser-Thr/Tyr_kinase_cat_dom"}, {"desc": "Tyrosine-protein kinase, receptor class II, conserved site", "id": "IPR002011", "short_desc": "Tyr_kinase_rcpt_2_CS"}, {"desc": "Low-density lipoprotein (LDL) receptor class A repeat", "id": "IPR002172", "short_desc": "LDrepeatLR_classA_rpt"}, {"desc": "Tyrosine-protein kinase, active site", "id": "IPR008266", "short_desc": "Tyr_kinase_AS"}, {"desc": "Protein kinase-like domain superfamily", "id": "IPR011009", "short_desc": "Kinase-like_dom_sf"}, {"desc": "Concanavalin A-like lectin/glucanase domain superfamily", "id": "IPR013320", "short_desc": "ConA-like_dom_sf"}, {"desc": "Protein kinase, ATP binding site", "id": "IPR017441", "short_desc": "Protein_kinase_ATP_BS"}, {"desc": "Tyrosine-protein kinase, catalytic domain", "id": "IPR020635", "short_desc": "Tyr_kinase_cat_dom"}, {"desc": "LDL receptor-like superfamily", "id": "IPR036055", "short_desc": "LDL_receptor-like_sf"}], "ipi": ["IPI00395632", "IPI00910903"], "map_location": "2p23.2-p23.1", "name": "ALK receptor tyrosine kinase", "other_names": ["ALK tyrosine kinase receptor", "CD246 antigen", "anaplastic lymphoma receptor tyrosine kinase", "mutant anaplastic lymphoma kinase"], "pantherdb": {"HGNC": "427", "_license": "http://pantherdb.org/tou.jsp", "ortholog": [{"MGI": "103305", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 10090, "uniprot_kb": "P97793"}, {"RGD": "628622", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 10116, "uniprot_kb": "F1LRZ0"}, {"Ensembl": "ENSGALG00000009034", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 9031, "uniprot_kb": "A0A3Q2U7B1"}, {"ZFIN": "ZDB-GENE-031027-1", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 7955, "uniprot_kb": "A0A0R4IRF5"}, {"WormBase": "WBGene00004740", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 6239, "uniprot_kb": "O76411"}, {"FlyBase": "FBgn0040505", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 7227, "uniprot_kb": "Q7KJ08"}], "uniprot_kb": "Q9UM73"}, "pathway": {"kegg": [{"id": "hsa05200", "name": "Pathways in cancer - Homo sapiens (human)"}, {"id": "hsa05223", "name": "Non-small cell lung cancer - Homo sapiens (human)"}, {"id": "hsa05235", "name": "PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)"}], "reactome": [{"id": "R-HSA-162582", "name": "Signal Transduction"}, {"id": "R-HSA-162582", "name": "Signal Transduction"}, {"id": "R-HSA-1643685", "name": "Disease"}, {"id": "R-HSA-201556", "name": "Signaling by ALK"}, {"id": "R-HSA-201556", "name": "Signaling by ALK"}, {"id": "R-HSA-5663202", "name": "Diseases of signal transduction by growth factor receptors and second messengers"}, {"id": "R-HSA-9006934", "name": "Signaling by Receptor Tyrosine Kinases"}, {"id": "R-HSA-9006934", "name": "Signaling by Receptor Tyrosine Kinases"}, {"id": "R-HSA-9700206", "name": "Signaling by ALK in cancer"}, {"id": "R-HSA-9700645", "name": "ALK mutants bind TKIs"}, {"id": "R-HSA-9700649", "name": "Drug resistance of ALK mutants"}, {"id": "R-HSA-9717264", "name": "ASP-3026-resistant ALK mutants"}, {"id": "R-HSA-9717301", "name": "NVP-TAE684-resistant ALK mutants"}, {"id": "R-HSA-9717316", "name": "alectinib-resistant ALK mutants"}, {"id": "R-HSA-9717319", "name": "brigatinib-resistant ALK mutants"}, {"id": "R-HSA-9717323", "name": "ceritinib-resistant ALK mutants"}, {"id": "R-HSA-9717326", "name": "crizotinib-resistant ALK mutants"}, {"id": "R-HSA-9717329", "name": "lorlatinib-resistant ALK mutants"}, {"id": "R-HSA-9725370", "name": "Signaling by ALK fusions and activated point mutants"}, {"id": "R-HSA-9851151", "name": "MDK and PTN in ALK signaling"}, {"id": "R-HSA-9851151", "name": "MDK and PTN in ALK signaling"}], "wikipathways": [{"id": "WP2848", "name": "Differentiation Pathway"}, {"id": "WP4255", "name": "Non-small cell lung cancer"}]}, "pdb": ["2KUP", "2KUQ", "2XB7", "2XBA", "2XP2", "2YFX", "2YHV", "2YJR", "2YJS", "2YS5", "2YT2", "3AOX", "3L9P", "3LCS", "3LCT", "4ANL", "4ANQ", "4ANS", "4CCB", "4CCU", "4CD0", "4CLI", "4CLJ", "4CMO", "4CMT", "4CMU", "4CNH", "4CTB", "4CTC", "4DCE", "4FNW", "4FNX", "4FNY", "4FNZ", "4FOB", "4FOC", "4FOD", "4JOA", "4MKC", "4TT7", "4Z55", "5A9U", "5AA8", "5AA9", "5AAA", "5AAB", "5AAC", "5FTO", "5FTQ", "5IMX", "5IUG", "5IUH", "5IUI", "5KZ0", "5VZ5", "6AT9", "6CDT", "6E0R", "6EBW", "6EDL", "6MX8", "7BTT", "7JY4", "7JYR", "7JYS", "7JYT", "7LRZ", "7LS0", "7MZW", "7MZY", "7N00", "7NWZ", "7NX3", "7NX4", "7R7K", "7R7R", "8ARJ"], "pfam": ["PF00629", "PF07714", "PF12810"], "pharmgkb": "PA24719", "pharos": {"target_id": 5309, "tdl": "Tclin"}, "prosite": ["PS50011", "PS50060"], "reagent": {"GNF_Qia_hs-genome_v1_siRNA": [{"id": "GNF245663", "relationship": "is"}, {"id": "GNF245664", "relationship": "is"}, {"id": "GNF245665", "relationship": "is"}, {"id": "GNF245666", "relationship": "is"}], "GNF_hs-druggable_lenti-shRNA": [{"id": "GNF079524", "relationship": "is"}, {"id": "GNF079525", "relationship": "is"}], "GNF_hs-druggable_plasmid-shRNA": [{"id": "GNF054231", "relationship": "is"}, {"id": "GNF059014", "relationship": "is"}, {"id": "GNF074329", "relationship": "is"}], "GNF_hs-druggable_siRNA": [{"id": "GNF069551", "relationship": "is"}, {"id": "GNF069552", "relationship": "is"}], "GNF_hs-oncomine_IDT-siRNA": [{"id": "GNF281634", "relationship": "is"}, {"id": "GNF281675", "relationship": "is"}, {"id": "GNF281716", "relationship": "is"}, {"id": "GNF281757", "relationship": "is"}], "GNF_hs-pkinase_IDT-siRNA": [{"id": "GNF166388", "relationship": "is"}, {"id": "GNF166389", "relationship": "is"}, {"id": "GNF166390", "relationship": "is"}, {"id": "GNF166391", "relationship": "is"}], "Invitrogen_IVTHSSIPKv2": [{"id": "GNF323712", "relationship": "is"}, {"id": "GNF323713", "relationship": "is"}], "NIBRI_hs-Secretome_pDEST": {"id": "GNF339136", "relationship": "is"}, "NOVART_hs-genome_siRNA": [{"id": "GNF093050", "relationship": "is"}, {"id": "GNF132748", "relationship": "is"}]}, "refseq": {"genomic": ["NC_000002.12", "NC_060926.1", "NG_009445.1"], "protein": ["NP_001340694.1", "NP_004295.2", "XP_054197220.1"], "rna": ["NM_001353765.2", "NM_004304.5", "XM_054341245.1", "XR_001738688.3", "XR_008486309.1"], "translation": [{"protein": "XP_054197220.1", "rna": "XM_054341245.1"}, {"protein": "NP_004295.2", "rna": "NM_004304.5"}, {"protein": "NP_001340694.1", "rna": "NM_001353765.2"}]}, "reporter": {"GNF1H": "gnf1h03839_s_at", "HG-U133_Plus_2": ["208211_s_at", "208212_s_at"], "HG-U95Av2": ["38543_at", "451_at"], "HTA-2_0": "TC02001708.hg.1", "HuEx-1_0": ["2475465", "2478748", "2546409", "3409041", "3409211"], "HuGene-1_1": ["7954559", "8041592", "8051241"], "HuGene-2_1": ["16879408", "16896049", "17120702", "17120704", "17120706"]}, "summary": "This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011].", "symbol": "ALK", "taxid": 9606, "type_of_gene": "protein-coding", "umls": {"cui": "C1332080"}, "unigene": "Hs.654469", "uniprot": {"Swiss-Prot": "Q9UM73", "TrEMBL": ["A0A0K2YUJ3", "B6D4Y2", "E7EPW7", "H7BZ33", "A0A087WZL3"]}, "wikipedia": {"url_stub": "Anaplastic lymphoma kinase"}}